ELSEVIER

International Journal of Pharmaceutics 230 (2001) 83–103

international journal of pharmaceutics

www.elsevier.com/locate/ijpharm

# Author Index Volumes 212–230 (2001)

Aaltonen, M.-L., see Nykänen, P. **229**, 155
Abimon, V.D., see Raghavan, C.V. **221**, 227
Aboul-Enein, H.Y., see Radwan, M.A. **217**, 111
Acharya, A., S.K. Sanyal, S.P. Moulik, Physicochemical investigations on microemulsification of eucalyptol and water in presence of polyoxyethylene (4) lauryl ether (Brij-30) and ethanol **229**, 213
Adams, E., D. Coomans, J. Smeyers-Verbeke, D.L. Massart, Application of linear mixed effects models to the evaluation of dissolution profiles **226**, 107
Adams, E., R. De Maesschalck, B. De Spiegeleer, Y. Vander Heyden, J. Smeyers-Verbeke, D.L. Massart, Evaluation of dissolution profiles using principal component analysis **212**, 41
Adeyeye, M.C., see Ichikawa, H. **216**, 67
Adeyeye, M.C., see Jain, A.C. **212**, 177
Agabeyoglu, I., see Eldem, T. **213**, 153
Agarwal, R., O.P. Katare, S.P. Vyas, Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol **228**, 43
Agarwal, V., I.K. Reddy, M.A. Khan, Polymethyacrylate based microparticulates of insulin for oral delivery: Preparation and in vitro dissolution stability in the presence of enzyme inhibitors **225**, 31
Ahola, M., see Kortesuo, P. **221**, 107
Ahola, M., see Rich, J. **212**, 121
Akova, M., see Eldem, T. **213**, 153
Alberti, I., Y.N. Kalia, A. Naik, J.-D. Bonny, R.H. Guy, Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo **219**, 11
Alderborn, G., see Berggren, J. **227**, 81
Alderborn, G., see Berggren, J. **219**, 113
Alderborn, G., see Tunón, Å. **222**, 65
Alencastre, J.B., see Netz, D.J.A. **213**, 117
Alexander, K., see Chatterjee, K. **213**, 31
Al Gamal, S.S., see El-Kamel, A.H. **220**, 13
Allémann, E., see Delie, F. **214**, 25
Allinson, J.G., R.J. Dansereau, A. Sakr, The effects of packaging on the stability of a moisture sensitive compound **221**, 49
Alonso, M.J., see De Campos, A.M. **224**, 159
Altorfer, H.R., see Horsch, P. **222**, 205
Alur, H.H., R.P. Desai, A.K. Mitra, T.P. Johnston, Inhibition of a model protease — pyroglutamate aminopeptidase by a natural oligosaccharide gum from *Hakea gibbosa* **212**, 171
Alvarez-Figueroa, M.J., J. Blanco-Méndez, Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions **215**, 57
Alvarez-Figueroa, M.J., M.B. Delgado-Charro, J. Blanco-Méndez, Passive and iontophoretic transdermal penetration of methotrexate **212**, 101
Alvarez, F.J., see Badawy, S.I.F. **223**, 1
Alvarez, J.M., see Simamora, P. **213**, 25
Amaral, J., see Bettencourt, A. **219**, 89
Ambrogi, V., G. Fardella, G. Grandolini, L. Perioli, Intercalation compounds of hydrotalcite-like anionic clays with antiinflammatory agents — I. Intercalation and in vitro release of ibuprofen **220**, 23
Amighi, K., see Eeckman, F. **222**, 259
Andreasen, K.H., see Lindhardt, K. **217**, 121
Andrès, C., P. Bracconi, Y. Pourcelot, On the difficulty of assessing the specific surface area of magnesium stearate **218**, 153
Andres, C., see Di Martino, P. **213**, 209
Antolič, G., F. Kozjek, S. Primožič, The relevance of nitrendipine erythrocyte partitioning for the variability of its bioavailability parameters **215**, 147
An, Z., see Pan, X. **220**, 33
Appel, M., see Brigger, I. **214**, 37
Arastoo, M., see Uchegbu, I.F. **224**, 185
Arbeille, B., see Boucaud, A. **228**, 69
Arican-Cellat, N., see Eldem, T. **213**, 153
Arima, H., see Nagase, Y. **229**, 163
Arletti, R., see Vandelli, M.A. **215**, 175
Armstrong, J.K., B.Z. Chowdhry, M.J. Snowden, J. Dong, S.A. Leharne, The effect of pH and concentration upon aggregation transitions in aqueous solutions of poloxamine T701 **229**, 57
Arnaud, P., see Zerrouk, N. **225**, 49
Asbill, C.S., see El-Kattan, A.F. **215**, 229
Ashurst, I.C., see Michael, Y. **221**, 165
Asiri, Y.A., see Khaled, K.A. **222**, 1
Assaf, S., see Gabboun, N.H. **212**, 73

PII: S0378-5173(01)00888-2

Assmus, M.W., see Gupta, V.K. **213**, 93
Attwood, D., see Brown, J.R. **213**, 127
Attwood, D., see Miyazaki, S. **229**, 29
Attwood, D., see Miyazaki, S. **220**, 161
Audus, K.L., see Hamilton, K.O. **228**, 171
Augustijns, P., see Maris, B. **213**, 143
Augustijns, P., see Six, K. **213**, 163
Augustijns, P., see Verheyen, S. **228**, 199
Avgoustakis, K., see Panagi, Z. **221**, 143
Awad, S., see Córdoba-Díaz, D. **226**, 61
Ayres, J.W., see Kapsi, S.G. **229**, 193
Azar, R., see Kambia, K. **229**, 139

Badawy, S.I.F., A.J. Gawronski, F.J. Alvarez, Application of sorption–desorption moisture transfer modeling to the study of chemical stability of a moisture sensitive drug product in different packaging configurations **223**, 1
Baert, L., see Rambali, B. **220**, 129
Baert, L., see Rambali, B. **220**, 149
Bagger, M., see Lindhardt, K. **217**, 121
Baillie, G., see Owens, M.D. **228**, 109
Bakker, H.H., see van Oosterhout, Y.V.J.M. **221**, 175
Bakker-Woudenberg, I.A.J.M., see Schiffelers, R.M. **214**, 103
Banker, G.S., see Zhu, L. **223**, 35
Barbeau, J., see Moisan, M. **226**, 1
Barber, T.A., see Driscoll, D.F. **219**, 21
Barichello, J.M., see Morishita, M. **212**, 289
Barnadas-Rodríguez, R., M. Sabés, Factors involved in the production of liposomes with a high-pressure homogenizer **213**, 175
Barry, B.W., see Mackay, K.M.B. **228**, 89
Barry, B.W., see Stott, P.W. **219**, 161
Barzegar Jalali, M., see Shokri, J. **228**, 99
Basit, A.W., L.F. Lacey, Colonic metabolism of ranitidine: implications for its delivery and absorption **227**, 157
Batavia, R., K.M.G. Taylor, D.Q.M. Craig, M. Thomas, The measurement of beclomethasone dipropionate entrapment in liposomes: a comparison of a microscope and an HPLC method **212**, 109
Bauer, K.H., see Tardi, C. **217**, 161
Beall, H.D., K.B. Sloan, Topical delivery of 5-fluorouracil (5-Fu) by 3-alkylcarbonyl-5-Fu prodrugs **217**, 127
Bechgaard, E., see Lindhardt, K. **217**, 121
Beckert, T.E., see Gupta, V.K. **213**, 93
Beckert, T.E., see Gupta, V.K. **213**, 83
Beezer, A.E., see Kierstan, K.T.E. **229**, 87
Beezer, A.E., see Zaman, F. **227**, 133
Beezer, A.E., see Zaman, F. **225**, 135
Belcheva, N., see Yoncheva, K. **226**, 31
Beletsi, A., see Panagi, Z. **221**, 143
Belleney, J., see Vaugelade, C. **229**, 67
Bender, J., see Berger, N. **223**, 55
Bentley, M.V.L.B., see Netz, D.J.A. **213**, 117
Berbenni, V., A. Marini, G. Bruni, A. Cardini, Thermoanalytical and spectroscopic characterisation of solid-state retinoic acid **221**, 123
Berger, N., A. Sachse, J. Bender, R. Schubert, M. Brandl, Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics **223**, 55
Berggren, J., G. Alderborn, Drying behaviour of two sets of microcrystalline cellulose pellets **219**, 113
Berggren, J., G. Alderborn, Effect of drying rate on porosity and tabletting behaviour of cellulose pellets **227**, 81
Bergonzi, M.C., see Bilia, A.R. **213**, 199
Berlanga, M., see Vázquez, J.L. **220**, 53
Bernkop-Schnürch, A., A.E. Clausen, M. Hnatyszyn, Thiolated polymers: synthesis and in vitro evaluation of polymer–cysteamine conjugates **226**, 185
Beronius, P., see Brounéus, F. **218**, 57
Berton, M., see Delie, F. **214**, 25
Besnard, M., see Brigger, I. **214**, 37
Bettencourt, A., A. Calado, J. Amaral, F.M. Vale, J.M.T. Rico, J. Monteiro, M. Castro, The influence of vacuum mixing on methylmethacrylate liberation from acrylic cement powder **219**, 89
Betz, G., P. Nowbakht, R. Imboden, G. Imanidis, Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro **228**, 147
Betz, G., R. Imboden, G. Imanidis, Interaction of liposome formulations with human skin in vitro **229**, 117
Bieber, T., see Fischer, D. **225**, 97
Bielinska, A.U., see Wu, H. **221**, 23
Biggio, G., see Franco, M. **225**, 63
Bigler, L., see Horsch, P. **222**, 205
Bilia, A.R., M.C. Bergonzi, F. Morgenni, G. Mazzi, F.F. Vincieri, Evaluation of chemical stability of St. John's wort commercial extract and some preparations **213**, 199
Billich, A., see Schmook, F.P. **215**, 51
Bistrian, B.R., see Driscoll, D.F. **219**, 21
Bjerregaard, S., H. Pedersen, H. Vedstesen, C. Vermehren, I. Söderberg, S. Frokjaer, Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: formulation, rheological characterisation and study of in vivo fate using whole body gamma-scintigraphy **215**, 13
Björk, E., see Dahlin, M. **212**, 267
Blackshaw, P.E., see Perkins, A.C. **222**, 295
Blanco-Méndez, J., see Alvarez-Figueroa, M.J. **215**, 57
Blanco-Méndez, J., see Alvarez-Figueroa, M.J. **212**, 101
Blanco-Prieto, M.J., see de Jalón, E.G. **226**, 181
Bodmeier, R., see Kranz, H. **212**, 11
Bodmeier, R., see Schmidt, C. **216**, 9
Bogataj, M., see Burjak, M. **224**, 123
Bolhuis, G.K., A.C. Eissens, E. Zoestbergen, DC Calcium lactate, a new filler-binder for direct compaction of tablets **221**, 77
Boneschans, B., see Zovko, M. **228**, 129
Bonina, F., see Puglia, C. **228**, 79
Bonneaux, F., see Zambaux, M.F. **212**, 1
Bonny, J.-D., see Alberti, I. **219**, 11
Boucaud, A., L. Machet, B. Arbeille, M.C. Machet, M. Sournac, A. Mavon, F. Patat, L. Vaillant, In vitro study of low-frequency ultrasound-enhanced transdermal transport

of fentanyl and caffeine across human and hairless rat skin **228**, 69
Boudad, H., P. Legrand, G. Lebas, M. Cheron, D. Duchêne, G. Ponchel, Combined hydroxypropyl-β-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir **218**, 113Bouwstra, J.A., see van den Bergh, B.A.I. **217**, 13
Bracconi, P., see Andrès, C. **218**, 153
Brandl, M., see Berger, N. **223**, 55
Brandl, M., see Tardi, C. **217**, 161
Brazeau, G.A., see Kranz, H. **212**, 11
Brigger, I., P. Chaminade, V. Marsaud, M. Appel, M. Besnard, R. Gurny, M. Renoir, P. Couvreur, Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation **214**, 37
Brion, F., see Micard, S. **212**, 93
Broeders, M.E.A.C., J. Molema, H.T.M. Folgering, Resistivities of placebo and active Diskus® inhalers compared **228**, 219
Broman, E., C. Khoo, L.S. Taylor, A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug **222**, 139
Brounéus, F., K. Karami, P. Beronius, L.-O. Sundelöf, Diffusive transport properties of some local anesthetics applicable for iontophoretic formulation of the drugs **218**, 57
Brown, J.R., J.H. Collett, D. Attwood, R.W. Ley, E.E. Sims, Physicochemical and biopharmaceutical characterization of BTA-243, a diacidic drug with low oral bioavailability **213**, 127
Brown, M.B., M. Hanpanitcharoen, G.P. Martin, An in vitro investigation into the effect of glycosaminoglycans on the skin partitioning and deposition of NSAIDs **225**, 113
Brown, M.D., A.G. Schätzlein, I.F. Uchegbu, Gene delivery with synthetic (non viral) carriers **229**, 1
Brunet, C., see Kambia, K. **229**, 139
Bruni, G., see Berbenni, V. **221**, 123
Brüsselbach, S., see Fischer, D. **225**, 97
Buckton, G., see Castile, J.D. **221**, 197
Buckton, G., see Chidavaenzi, O.C. **216**, 43
Buckton, G., see Hogan, S.E. **227**, 57
Buckton, G., see Newell, H.E. **217**, 45
Bulacovschi, V., see Fundueanu, G. **218**, 13
Bunel, C., see Vaugelade, C. **229**, 67
Burel, F., see Vaugelade, C. **229**, 67
Burgalassi, S., see Di Colo, G. **220**, 169
Burgalassi, S., see Di Colo, G. **215**, 101
Burgalassi, S., see Monti, D. **229**, 131
Bürger, C., D. Valcarenghi, S. Sandri, C.A. Rodrigues, Cross-linking chitosan-Fe(III), an oral phosphate binder: studies in vitro and in vivo **223**, 29
Burjak, M., M. Bogataj, M. Velnar, I. Grabnar, A. Mrhar, The study of drug release from microspheres adhered on pig vesical mucosa **224**, 123
Burt, H.M., see Liggins, R.T. **222**, 19
Bush, D., see Jackson, S.J. **212**, 55
Butler, D.A., see Newell, H.E. **217**, 45
Byun, Y., see Choi, Y. **215**, 67
Caballero-Quintero, A., A. Piñeyro-López, N. Waksman, In vitro binding studies of the peroxisomicine A1–BSA and –HSA interactions **229**, 23
Cadelli, G., see Grassi, M. **229**, 95
Calado, A., see Bettencourt, A. **219**, 89
Cal, K., S. Janicki, M. Sznitowska, In vitro studies on penetration of terpenes from matrix-type transdermal systems through human skin **224**, 81
Cámara, M.S., see Collado, M.S. **229**, 205
Camber, O., see Hedenus, P. **224**, 207
Cappello, B., C. Carmignani, M. Iervolino, M. Immacolata La Rotonda, M. Fabrizio Saettone, Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water-soluble polymers: in vitro/in vivo studies **213**, 75
Cappello, B., see Iervolino, M. **212**, 131
Cardini, A., see Berbenni, V. **221**, 123
Carmignani, C., see Cappello, B. **213**, 75
Carpov, A., see Fundueanu, G. **218**, 13
Carrascosa, C., see Torrado, G. **217**, 193
Carteni, M., see Morana, A. **230**, 47
Cartilier, L., see Chebli, C. **222**, 183
Castile, J.D., K.M.G. Taylor, G. Buckton, The influence of incubation temperature and surfactant concentration on the interaction between dimyristoylphosphatidylcholine liposomes and poloxamer surfactants **221**, 197
Castro, M., see Bettencourt, A. **219**, 89
Cerezo, P., see Viseras, C. **217**, 201
Chai, C.-Y., see Wu, P.-C. **222**, 225
Chaminade, P., see Brigger, I. **214**, 37
Chang, J.-S., see Wu, P.-C. **222**, 225
Chang, J.Y., see Kim, C.-K. **220**, 141
Chang, S.-J., see Kim, K.-E. **217**, 101
Chang, S.-Y., see Park, E.-S. **218**, 167
Chan, L.W., W.Y. Chan, P.W.S. Heng, An improved method for the measurement of colour uniformity in pellet coating **213**, 63
Chan, S.Y., see Vaddi, H.K. **212**, 247
Chan, W.Y., see Chan, L.W. **213**, 63
Chatterjee, K., D. Dollimore, K. Alexander, A new application for the Antoine equation in formulation development **213**, 31
Chattopadhyay, P., R.B. Gupta, Production of griseofulvin nanoparticles using supercritical $CO_2$ antisolvent with enhanced mass transfer **228**, 19
Chaw, C.S., E. Yazaki, D.F. Evans, The effect of pH change on the gastric emptying of liquids measured by electrical impedance tomography and pH-sensitive radiotelemetry capsule **227**, 167
Chebli, C., L. Cartilier, N.G. Hartman, Substituted amylose as a matrix for sustained-drug release: a biodegradation study **222**, 183
Chemtob, C., see Zerrouk, N. **225**, 49
Chen, K.-j., see Krishna, G. **222**, 77
Chen, Y., see Guo, J. **216**, 17
Cheron, M., see Boudad, H. **218**, 113
Chetoni, P., see Di Colo, G. **220**, 169
Chetoni, P., see Di Colo, G. **215**, 101

Chetoni, P., see Monti, D. **229**, 131
Chiba, Y., see Morishita, M. **212**, 289
Chicco, D., see Hreczuk-Hirst, D. **230**, 57
Chidavaenzi, O.C., G. Buckton, F. Koosha, The effect of co-spray drying with polyethylene glycol 4000 on the crystallinity and physical form of lactose **216**, 43
Chikhale, P.J., see Gharat, L. **219**, 1
Chi, S.-C., see Park, E.-S. **218**, 167
Chi, S.-C., see Rhee, Y.-S. **228**, 161
Chiu, W.-T., see Fang, J.-Y. **219**, 61
Chiu, W.-T., see Wang, Y.-Y. **224**, 89
Cho, C.-W., see Shin, S.-C. **222**, 199
Choi, H.-G., see Kim, C.-K. **220**, 141
Choi, H.-G., see Lee, E.-J. **218**, 125
Choi, H.-G., see Yong, C.S. **226**, 195
Choi, J.-G., see Rhee, Y.-S. **228**, 161
Choi, J.S., see Yong, C.S. **226**, 195
Choi, Y., S.Y. Kim, S.H. Kim, K.-S. Lee, C. Kim, Y. Byun, Long-term delivery of all-*trans*-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres **215**, 67
Cho, M.K., see Kim, Y.G. **229**, 45
Chow, A.H.L., see Yin, O.Q.P. **222**, 305
Chowdhry, B.Z., see Armstrong, J.K. **229**, 57
Chowdhry, B.Z., see Michael, Y. **221**, 165
Cho, W.-J., see Kim, K.-E. **217**, 101
Chow, M.S.S., see Yin, O.Q.P. **222**, 305
Christensen, K.L., G.P. Pedersen, H.G. Kristensen, Preparation of redispersible dry emulsions by spray drying **212**, 187
Christensen, K.L., G.P. Pedersen, H.G. Kristensen, Technical optimisation of redispersible dry emulsions **212**, 195
Chung, S.J., see Kim, Y.G. **229**, 45
Chung, S.-J., see Lee, Y.-J. **224**, 201
Chung, T.-W., Y.-Y. Huang, Y.-Z. Liu, Effects of the rate of solvent evaporation on the characteristics of drug loaded PLLA and PDLLA microspheres **212**, 161
Chu, W.A., see Johnston, T.P. **229**, 75
Ciftci, K., R.J. Levy, Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts **218**, 81
Clark, B.J., see Jouyban-Gharamaleki, A. **216**, 33
Clarkson, Q., see Zaman, F. **227**, 133
Clarkson, Q., see Zaman, F. **225**, 135
Clas, S.-D., see Hancock, B.C. **228**, 139
Clausen, A.E., see Bernkop-Schnürch, A. **226**, 185
Coiffard, L.J.M., see Couteau, C. **222**, 153
Collado, M.S., J.C. Robles, M. De Zan, M.S. Cámara, V.E. Mantovani, H.C. Goicoechea, Determination of dexamethasone and two excipients (creatinine and propylparaben) in injections by using UV-spectroscopy and multivariate calibrations **229**, 205
Collett, J.H., see Brown, J.R. **213**, 127
Colombo, P., see Nicoli, S. **214**, 31
Connan, A.E., see Couteau, C. **222**, 153
Constantin, M., see Fundueanu, G. **218**, 13
Coomans, D., see Adams, E. **226**, 107
Córdoba-Borrego, M., see Córdoba-Díaz, D. **226**, 61
Córdoba-Díaz, D., M. Córdoba-Díaz, S. Awad, M. Córdoba-Borrego, Effect of pharmacotechnical design on the in vitro interaction of ketoconazole tablets with non-systemic antacids **226**, 61
Córdoba-Díaz, M., see Córdoba-Díaz, D. **226**, 61
Corrigan, O.I., see Killen, B.U. **228**, 189
Corrigan, O.I., see O'Connor, K.M. **226**, 163
Corrigan, O.I., see O'Connor, K.M. **222**, 281
Costa, P., An alternative method to the evaluation of similarity factor in dissolution testing **220**, 77
Couarraze, G., see Nicoli, S. **214**, 31
Couarraze, G., see Sommier, N. **222**, 243
Couet, W., see Olivier, J.-C. **213**, 187
Couteau, C., N. Perez Cullel, A.E. Connan, L.J.M. Coiffard, Stripping method to quantify absorption of two sunscreens in human **222**, 153
Couvreur, P., see Brigger, I. **214**, 37
Couvreur, P., see Lambert, G. **214**, 13
Couvreur, P., see Nicoli, S. **214**, 31
Craig, D.Q.M., see Batavia, R. **212**, 109
Craig, D.Q.M., see Khatri, L. **227**, 121
Crail, D., see McCargar, L. **222**, 191
Crommelin, D.J.A., see Stenekes, R.J.H. **214**, 17
Crommelin, D.J.A., see Verbaan, F.J. **214**, 99

Dahlin, M., E. Björk, Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats **212**, 267
Dalmora, M.E., S.L. Dalmora, A.G. Oliveira, Inclusion complex of piroxicam with β-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect **222**, 45
Dalmora, S.L., see Dalmora, M.E. **222**, 45
Dalton, C.R., see Hancock, B.C. **228**, 139
Danjo, K., see Todo, H. **220**, 101
Dansereau, R.J., see Allinson, J.G. **221**, 49
Dansereau, R.J., see Perkins, A.C. **222**, 295
Dansereau, R., see McCargar, L. **222**, 191
D'Arbigny, P., see Hoizey, G. **229**, 147
Darwis, Y., I.W. Kellaway, Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes **215**, 113
Dash, A.K., see Fan, H. **213**, 103
Dashbolaghi, A., see Shokri, J. **228**, 99
Davidsen, J., C. Vermehren, S. Frokjaer, O.G. Mouritsen, K. Jørgensen, Drug delivery by phospholipase $A_2$ degradable liposomes **214**, 67
Davies-Cutting, C.J., see Michael, Y. **221**, 165
Davis, A.F., see Kierstan, K.T.E. **229**, 87
Davis, A.F., see Raghavan, S.L. **221**, 95
Davis, A.F., see Raghavan, S.L. **212**, 213
Davis, A.F., see Zaman, F. **227**, 133
Davis, A.F., see Zaman, F. **225**, 135
Davis, J.A., see Riley, R.G. **217**, 87
Davis, S.S., see Han, J. **215**, 207
Davis, S.S., see Illum, L. **222**, 109
Davis, S.S., see Soane, R.J. **217**, 183
Dawson, G., see Reason, M. **222**, 121

Deasy, P.B., see Levis, S.R. **230**, 25
Deasy, P.B., see Levis, S.R. **213**, 13
De Campos, A.M., A. Sánchez, M.J. Alonso, Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A **224**, 159
DeCrosta, M.T., J.B. Schwartz, R.J. Wigent, K. Marshall, Thermodynamic analysis of compact formation; compaction, unloading, and ejection: II. Mechanical energy (work) and thermal energy (heat) determinations of compact unloading and ejection **213**, 45
De Guidi, G., see Pignatello, R. **218**, 27
de Jalón, E.G., M.J. Blanco-Prieto, P. Ygartua, S. Santoyo, PLGA microparticles: possible vehicles for topical drug delivery **226**, 181
De Kerf, M., W. Mondelaers, P. Lahorte, C. Vervaet, J.P. Remon, Characterisation and disintegration properties of irradiated starch **221**, 69
Delgado-Charro, M.B., see Alvarez-Figueroa, M.J. **212**, 101
Delie, F., M. Berton, E. Allémann, R. Gurny, Comparison of two methods of encapsulation of an oligonucleotide into poly(D,L-lactic acid) particles **214**, 25
Dellacherie, E., see Zambaux, M.F. **212**, 1
del Pozo, A., see Medina, J. **216**, 1
De Maesschalck, R., see Adams, E. **212**, 41
Demeester, J., see Vergote, G.J. **219**, 81
Desai, R.P., see Alur, H.H. **212**, 171
De Smedt, S., see Vergote, G.J. **219**, 81
De Spiegeleer, B., see Adams, E. **212**, 41
Dettmar, P.W., see Riley, R.G. **217**, 87
de Witte, T., see van Oosterhout, Y.V.J.M. **221**, 175
De Zan, M., see Collado, M.S. **229**, 205
Dias, M., S.L. Raghavan, J. Hadgraft, ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes **216**, 51
Di Colo, G., S. Burgalassi, P. Chetoni, M.P. Fiaschi, Y. Zambito, M.F. Saettone, Gel-forming erodible inserts for ocular controlled delivery of ofloxacin **215**, 101
Di Colo, G., S. Burgalassi, P. Chetoni, M.P. Fiaschi, Y. Zambito, M.F. Saettone, Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide) **220**, 169
Di Martino, P., M. Scoppa, E. Joiris, G.F. Palmieri, C. Andres, Y. Pourcelot, S. Martelli, The spray drying of acetazolamide as method to modify crystal properties and to improve compression behaviour **213**, 209
Dine, T., see Kambia, K. **229**, 139
Djilani, M., see Olivier, J.-C. **213**, 187
D'mello, A.P., see Habibi-Moini, S. **215**, 185
Dobreva, Z., see Zheleva, A. **222**, 237
Doležal, P., see Klimeš, J. **217**, 153
Doliwa, A., S. Santoyo, P. Ygartua, Effect of passive and iontophoretic skin pretreatments with terpenes on the in vitro skin transport of piroxicam **229**, 37
Dollimore, D., see Chatterjee, K. **213**, 31
Dolovich, M., see Dubus, J.-C. **222**, 101
Doménech, Ò., see Vázquez, J.L. **220**, 53
Dong, J., see Armstrong, J.K. **229**, 57
Dortunç, B., see Sipahigil, O. **228**, 119
Drechsler, M., see Tardi, C. **217**, 161
Driscoll, D.F., F. Etzler, T.A. Barber, J. Nehne, W. Niemann, B.R. Bistrian, Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction **219**, 21
Dubus, J.-C., R. Rhem, M. Dolovich, Delivery of HFA and CFC salbutamol from spacer devices used in infancy **222**, 101
Duchêne, D., see Boudad, H. **218**, 113
Duchêne, D., see Montisci, M.-J. **215**, 153
Duclos, R., see Vaugelade, C. **229**, 67
Dugue, J., see Zerrouk, N. **225**, 49
Dukic, S., see Hoizey, G. **229**, 147
Duncan, R., see Hreczuk-Hirst, D. **230**, 57
Dureja, H., A.K. Tiwary, S. Gupta, Simulation of skin permeability in chitosan membranes **213**, 193

Eaimtrakarn, S., Y. Itoh, J.-i. Kishimoto, Y. Yoshikawa, N. Shibata, K. Takada, Retention and transit of intestinal mucoadhesive films in rat small intestine **224**, 61
Eeckman, F., K. Amighi, A.J. Moës, Effect of some physiological and non-physiological compounds on the phase transition temperature of thermoresponsive polymers intended for oral controlled-drug delivery **222**, 259
Eissens, A.C., see Bolhuis, G.K. **221**, 77
Ek, R., see Hedenus, P. **224**, 207
Eldem, T., N. Arican-Cellat, I. Agabeyoglu, M. Akova, E. Kansu, Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients **213**, 153
El-Kamel, A.H., M.S. Sokar, S.S. Al Gamal, V.F. Naggar, Preparation and evaluation of ketoprofen floating oral delivery system **220**, 13
El-Kattan, A.F., C.S. Asbill, N. Kim, B.B. Michniak, The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities **215**, 229
Elliot, J., see Zaman, F. **227**, 133
Elliot, J., see Zaman, F. **225**, 135
Elmi, M.M., M.N. Sarbolouki, A simple method for preparation of immuno-magnetic liposomes **215**, 45
Elsässer, H.-P., see Fischer, D. **225**, 97
El-Sayed, M., see Tajarobi, F. **215**, 263
El-Sayed, Y.M., see Khaled, K.A. **222**, 1
Elujoba, A.A., see Orafidiya, L.O. **224**, 177
Endo, K., see Miyazaki, S. **229**, 29
Endo, K., see Miyazaki, S. **220**, 161
Esposito, E., see Fundueanu, G. **218**, 13
Etzler, F., see Driscoll, D.F. **219**, 21
Evangelatos, G., see Panagi, Z. **221**, 143
Evans, B., see Sabir, A. **215**, 123
Evans, D.F., see Chaw, C.S. **227**, 167
Evers, S., see van Oosterhout, Y.V.J.M. **221**, 175
Evesque, P., see Sommier, N. **222**, 243
Ezra, A., see Hoffman, A. **220**, 1

Fabrizio Saettone, M., see Cappello, B. **213**, 75
Fahmy, S., see Olivier, J.-C. **213**, 187
Fang, J.-Y., C.-T. Hong, W.-T. Chiu, Y.-Y. Wang, Effect of liposomes and niosomes on skin permeation of enoxacin **219**, 61
Fang, J.-Y., see Wang, Y.-Y. **224**, 89
Fang, J.-Y., S.-Y. Yu, P.-C. Wu, Y.-B. Huang, Y.-H. Tsai, In vitro skin permeation of estradiol from various proniosome formulations **215**, 91
Fan, H., A.K. Dash, Effect of cross-linking on the in vitro release kinetics of doxorubicin from gelatin implants **213**, 103
Farag Badawy, S.I., Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms **223**, 81
Fardella, G., see Ambrogi, V. **220**, 23
Farkas, E., R. Zelkó, G. Török, I. Rácz, S. Marton, Influence of chlorhexidine species on the liquid crystalline structure of vehicle **213**, 1
Fatibello-Filho, O., see Teixeira, M.F.S. **221**, 115
Fattal, E., see Lambert, G. **214**, 13
Fattal, E., see Nicoli, S. **214**, 31
Fell, J.T., see Khan, H. **227**, 113
Fell, J.T., see Ofori-Kwakye, K. **226**, 139
Fernandes, A.I., G. Gregoriadis, The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics **217**, 215
Fernandes, C.M., see Stenekes, R.J.H. **214**, 17
Fernández-de Córdova, M.L., see Ruiz-Medina, A. **216**, 95
Ferro, M., see Pignatello, R. **218**, 27
Fiaschi, M.P., see Di Colo, G. **220**, 169
Fiaschi, M.P., see Di Colo, G. **215**, 101
Figaszewski, Z., see Szachowicz-Petelska, B. **222**, 169
Filipović-Grčić, J., see Moneghini, M. **222**, 129
Fischer, D., T. Bieber, S. Brüsselbach, H.-P. Elsässer, T. Kissel, Cationized human serum albumin as a non-viral vector system for gene delivery? Characterization of complex formation with plasmid DNA and transfection efficiency **225**, 97
Fisher, A.N., see Illum, L. **222**, 109
Florence, A.T., Editorial Note **215**, 1
Florence, A.T., see Purohit, G. **214**, 71
Florence, A.T., see Sakthivel, T. **214**, 43
Florence, A.T., see Yanai, S. **214**, 49
Folgering, H.T.M., see Broeders, M.E.A.C. **228**, 219
Fooladi, S., see Ghafourian, T. **217**, 1
Ford, J.L., see Hino, T. **226**, 53
Ford, J.L., see Hino, T. **219**, 39
Forni, F., see Vandelli, M.A. **215**, 175
Forster, A., J. Hempenstall, I. Tucker, T. Rades, Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis **226**, 147
Forte, C., see Pignatello, R. **218**, 27
Franco, M., G. Trapani, A. Latrofa, C. Tullio, M.R. Provenzano, M. Serra, M. Muggironi, G. Biggio, G. Liso, Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions **225**, 63
Franco, M., see Puglia, C. **228**, 79
Franz, S.F., see Viegas, T.X. **219**, 73
Franz, T.J., see Viegas, T.X. **219**, 73
Freichel, O.L., B.C. Lippold, An easy producible new oral hydrocolloid drug delivery system with a late burst in the release profile **216**, 165
Friedrich, J., see Vignardet, C. **224**, 115
Frier, M., see Perkins, A.C. **222**, 295
Friis, G.J., see Larsen, S.W. **230**, 67
Friis, G.J., see Larsen, S.W. **216**, 83
Frijlink, H.W., see Hinrichs, W.L.J. **215**, 163
Frokjaer, S., see Bjerregaard, S. **215**, 13
Frokjaer, S., see Davidsen, J. **214**, 67
Frokjaer, S., see Pedersen, T.B. **214**, 77
Frokjaer, S., see Vermehren, C. **214**, 93
Frutos, G., see Torrado, S. **217**, 57
Frutos, P., see Torrado, S. **217**, 57
Fujii, M., K. Shiozawa, Y. Watanabe, M. Matsumoto, Effect of phosphatidylcholine on skin permeation of indomethacin from gel prepared with liquid paraffin and hydrogenated phospholipid **222**, 57
Fujikawa, M., see Obata, Y. **212**, 223
Fujimoto, R., see Yokota, S. **223**, 69
Fujioka, K., see Ichikawa, H. **216**, 67
Fukui, E., N. Miyamura, M. Kobayashi, Effect of magnesium stearate or calcium stearate as additives on dissolution profiles of diltiazem hydrochloride from press-coated tablets with hydroxypropylmethylcellulose acetate succinate in the outer shell **216**, 137
Fukui, E., N. Miyamura, T. Yoneyama, M. Kobayashi, Drug release from and mechanical properties of press-coated tablets with hydroxypropylmethylcellulose acetate succinate and plasticizers in the outer shell **217**, 33
Fukui, H., see Nakamichi, K. **218**, 103
Fukumori, Y., see Ichikawa, H. **216**, 67
Fukushima, S., see Yokota, S. **223**, 69
Fundueanu, G., G. Mocanu, M. Constantin, A. Carpov, V. Bulacovschi, E. Esposito, C. Nastruzzi, Acrylic microspheres for oral controlled release of the biguanide buformin **218**, 13

Gabboun, N.H., N.M. Najib, H.G. Ibrahim, S. Assaf, Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin **212**, 73
Gabor, F., U. Klausegger, M. Wirth, The Interaction between wheat germ agglutinin and other plant lectins with prostate cancer cells Du-145 **221**, 35
Gadjeva, V.G., see Zheleva, A.M. **212**, 257
Gallori, S., see Mulinacci, N. **216**, 23
Gander, B., see Pálinkó-Biró, E. **221**, 153
G. Antimisiaris, S., see Kallinteri, P. **221**, 219
Gasco, M.R., see Peira, E. **226**, 47
Gašperlin, M., see Špiclin, P. **222**, 271
Gawronski, A.J., see Badawy, S.I.F. **223**, 1

Gebauer, M.G., A.F. McClure, T.L. Vlahakis, Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel **223**, 49
General, S., A.F. Thünemann, pH-sensitive nanoparticles of poly(amino acid) dodecanoate complexes **230**, 11
Geppi, M., see Pignatello, R. **218**, 27
German, L., see Hreczuk-Hirst, D. **230**, 57
Gessner, A., C. Olbrich, W. Schröder, O. Kayser, R.H. Müller, The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles **214**, 87
Ghafourian, T., see Shokri, J. **228**, 99
Ghafourian, T., S. Fooladi, The effect of structural QSAR parameters on skin penetration **217**, 1
Ghandehari, H., see Tajarobi, F. **215**, 263
Gharat, L., R. Taneja, N. Weerapreeyakul, B. Rege, J. Polli, P.J. Chikhale, Targeted drug delivery systems 6: Intracellular bioreductive activation, uptake and transport of an anticancer drug delivery system across intestinal Caco-2 cell monolayers **219**, 1
Giaccherini, C., see Mulinacci, N. **216**, 23
Giannelli, R., see Monti, D. **229**, 131
Giovannuci, G., see Montisci, M.-J. **215**, 153
Gleditsch, E., P.J. Waaler, Accelerated stability studies of morphine injections in plastic ampoules **212**, 275
Goicoechea, H.C., see Collado, M.S. **229**, 205
Golomb, G., see Hoffman, A. **220**, 1
Gönen, S., see Nair, R. **225**, 83
Göpferich, A., see Reithmeier, H. **218**, 133
Grabnar, I., see Burjak, M. **224**, 123
Grandolini, G., see Ambrogi, V. **220**, 23
Grant, D.J.W., see Sun, C. **215**, 221
Grant, D.J.W., see Zhu, H. **215**, 251
Grassi, M., G. Cadelli, Theoretical considerations on the in vivo intestinal permeability determination by means of the single pass and recirculating techniques **229**, 95
Gray, A.I., see Uchegbu, I.F. **230**, 77
Gray, A.I., see Uchegbu, I.F. **224**, 185
Gref, R., see Zambaux, M.F. **212**, 1
Gregoriadis, G., see Fernandes, A.I. **217**, 215
Gressier, B., see Kambia, K. **229**, 139
Guccione, S., see Pignatello, R. **218**, 27
Guerra, P., see Vandelli, M.A. **215**, 175
Guillaume, Y.C., see Vignardet, C. **224**, 115
Gulik, A., see Lambert, G. **214**, 13
Guðmundsdóttir, H., see Loftsson, T. **212**, 29
Guo, J., Q. Ping, Y. Chen, Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and sandimmun neoral **216**, 17
Gupta, R.B., see Chattopadhyay, P. **228**, 19
Gupta, S., see Dureja, H. **213**, 193
Gupta, S., see Ni, N. **226**, 39
Gupta, V.K., M.W. Assmus, T.E. Beckert, J.C. Price, A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables **213**, 93
Gupta, V.K., T.E. Beckert, J.C. Price, A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development **213**, 83
Gurley, B., see Kommuru, T.R. **212**, 233
Gurny, R., see Brigger, I. **214**, 37
Gurny, R., see Delie, F. **214**, 25
Güven, O., see Savaş, H. **224**, 151
Guy, R.H., see Alberti, I. **219**, 11
Guy, R.H., see Moser, K. **224**, 169

Habibi-Moini, S., A.P. D'mello, Evaluation of possible reasons for the low phenylalanine ammonia lyase activity in cellulose nitrate membrane microcapsules **215**, 185
Hadgraft, J., see Dias, M. **216**, 51
Hadgraft, J., see Iervolino, M. **212**, 131
Hadgraft, J., see Kierstan, K.T.E. **229**, 87
Hadgraft, J., see Raghavan, S.L. **221**, 95
Hadgraft, J., see Raghavan, S.L. **212**, 213
Hadgraft, J., see Valenta, C. **217**, 79
Hadgraft, J., Skin, the final frontier **224**, 1
Hahn, H., see Schöler, N. **221**, 57
Hahn, M., see Park, E.-S. **218**, 167
Halbert, G.W., see Owens, M.D. **228**, 109
Hamada, H., see Sugano, K. **228**, 181
Hamilton, K.O., M.A. Yazdanian, K.L. Audus, Modulation of P-glycoprotein activity in Calu-3 cells using steroids and β-ligands **228**, 171
Hampson, F., see Riley, R.G. **217**, 87
Hancock, B.C., C.R. Dalton, S.-D. Clas, Micro-scale measurement of the mechanical properties of compressed pharmaceutical powders. 2: The dynamic moduli of microcrystalline cellulose **228**, 139
Han, J., S.S. Davis, C. Washington, Physical properties and stability of two emulsion formulations of propofol **215**, 207
Hanna, M., see Jouyban-Gharamaleki, A. **216**, 33
Hanpanitcharoen, M., see Brown, M.B. **225**, 113
Harashima, H., see Huong, T.M. **215**, 197
Harashima, H., see Ishida, T. **224**, 69
Hartman, N.G., see Chebli, C. **222**, 183
Hasegawa, T., see Sugibayashi, K. **219**, 107
Hashida, M., see Verbaan, F.J. **214**, 99
Hassan, M., see Micard, S. **212**, 93
Hassan-Zadeh, D., see Shokri, J. **228**, 99
Hatanaka, T., see Katayama, K. **226**, 69
Hathaway, S., see Perkins, A.C. **222**, 295
Hautbout, G., see Tromelin, A. **224**, 131
Hellen, L., see Korhonen, M. **221**, 187
Hempenstall, J., see Forster, A. **226**, 147
Heng, P.W.S., see Chan, L.W. **213**, 63
Hennink, W.E., see Stenekes, R.J.H. **214**, 17
Hennink, W.E., see Verbaan, F.J. **214**, 99
Hernández-Borrell, J., see Vázquez, J.L. **220**, 53
Herrmann, J., see Reithmeier, H. **218**, 133
Higashiyama, K., see Obata, Y. **212**, 223
Higo, N., see Nakamura, K. **218**, 93
Hill, R.M., A quantified analysis of the dielectric dispersion in a simple emulsion system **227**, 139

Hinchcliffe, M., see Soane, R.J. **217**, 183
Hino, T., J.L. Ford, Characterization of the hydroxypropylmethylcellulose–nicotinamide binary system **219**, 39
Hino, T., J.L. Ford, Effect of nicotinamide on the properties of aqueous HPMC solutions **226**, 53
Hinrichs, W.L.J., M.G. Prinsen, H.W. Frijlink, Inulin glasses for the stabilization of therapeutic proteins **215**, 163
Hirata, M., see Nagase, Y. **229**, 163
Hirayama, F., see Nagase, Y. **229**, 163
Hirvonen, J., see Korhonen, M. **221**, 187
Hnatyszyn, M., see Bernkop-Schnürch, A. **226**, 185
Hoag, S.W., see Nair, R. **225**, 83
Hoffman, A., D. Stepensky, A. Ezra, J.M. Van Gelder, G. Golomb, Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination **220**, 1
Hogan, S.E., G. Buckton, Water sorption/desorption—near IR and calorimetric study of crystalline and amorphous raffinose **227**, 57
Hoizey, G., M.L. Kaltenbach, S. Dukic, D. Lamiable, H. Millart, P. D'Arbigny, R. Vistelle, Pharmacokinetics of gacyclidine enantiomers in plasma and spinal cord after single enantiomer administration in rats **229**, 147
Hong, C.-T., see Fang, J.-Y. **219**, 61
Hong, C.-T., see Wang, Y.-Y. **224**, 89
Ho, P.C., see Vaddi, H.K. **212**, 247
Horikiri, Y., see Morita, T. **219**, 127
Horsch, P., L. Bigler, H.R. Altorfer, Influence of radiation sterilization on the stability of trifluorothymidine **222**, 205
Hoste, S., see Vergote, G.J. **219**, 81
Hreczuk-Hirst, D., D. Chicco, L. German, R. Duncan, Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups **230**, 57
Huang, Y.-B., see Fang, J.-Y. **215**, 91
Huang, Y.-B., see Wu, P.-C. **222**, 225
Huang, Y.-Y., see Chung, T.-W. **212**, 161
Huong, T.M., T. Ishida, H. Harashima, H. Kiwada, The complement system enhances the clearance of phosphatidylserine (PS)-liposomes in rat and guinea pig **215**, 197
Hussain, N., Fluorometric method for the simultaneous quantitation of differently-sized nanoparticles in rodent tissue **214**, 55
Hwang, Y.-Y., see Kim, C.-K. **220**, 141

Ibrahim, H.G., see Gabboun, N.H. **212**, 73
Ichikawa, H., K. Fujioka, M.C. Adeyeye, Y. Fukumori, Use of ion-exchange resins to prepare 100 μm-sized microcapsules with prolonged drug-release by the Wurster process **216**, 67
Ichimura, F., see Yokogawa, K. **229**, 183
Iervolino, M., B. Cappello, S.L. Raghavan, J. Hadgraft, Penetration enhancement of ibuprofen from supersaturated solutions through human skin **212**, 131
Iervolino, M., see Cappello, B. **213**, 75
Iida, K., see Todo, H. **220**, 101
Ikeda, M., see Watanabe, T. **226**, 81
Illum, L., A.N. Fisher, I. Jabbal-Gill, S.S. Davis, Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides **222**, 109
Illum, L., see Soane, R.J. **217**, 183
Imanidis, G., see Betz, G. **229**, 117
Imanidis, G., see Betz, G. **228**, 147
Imboden, R., see Betz, G. **229**, 117
Imboden, R., see Betz, G. **228**, 147
Immacolata La Rotonda, M., see Cappello, B. **213**, 75
Irie, T., see Nagase, Y. **229**, 163
Iseki, K., see Kobayashi, M. **221**, 87
Ishida, T., K. Yasukawa, H. Kojima, H. Harashima, H. Kiwada, Effect of cholesterol content in activation of the classical versus the alternative pathway of rat complement system induced by hydrogenated egg phosphatidylcholine-based liposomes **224**, 69
Ishida, T., see Huong, T.M. **215**, 197
Ishikawa, F., M. Katsura, I. Tamai, A. Tsuji, Improved nasal bioavailability of elcatonin by insoluble powder formulation **224**, 105
Ishizaki, J., see Yokogawa, K. **229**, 183
Isobe, T., see Watanabe, T. **226**, 81
Isowa, K., see Obata, Y. **212**, 223
Ithakissios, D.S., see Panagi, Z. **221**, 143
Itoh, T., see Kohda-Shimizu, R. **220**, 119
Itoh, Y., see Eaimtrakarn, S. **224**, 61
Ito, K., see Kohda-Shimizu, R. **220**, 119
Izumi, S., see Nakamichi, K. **218**, 103

Jabbal-Gill, I., see Illum, L. **222**, 109
Jacknowitz, A.I., see Prabhu, S. **217**, 71
Jackson, S.J., D. Bush, A.C. Perkins, Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate **212**, 55
Jacobs, C., O. Kayser, R.H. Müller, Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone **214**, 3
Jain, A.C., M.C. Adeyeye, Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether β-cyclodextrins (SBE) and danazol–SBE inclusion complexes **212**, 177
Jain, A.K., see Panchagnula, R. **219**, 95
Jain, N., G. Yang, S.E. Tabibi, S.H. Yalkowsky, Solubilization of NSC-639829 **225**, 41
Jain, R.A., see Vergote, G.J. **219**, 81
Jain, S., see Sabir, A. **215**, 123
Jaitely, V., see Sakthivel, T. **214**, 43
Janicki, S., see Cal, K. **224**, 81
Jans, E., see Rambali, B. **220**, 129
Jarho, P., see Suihko, E. **215**, 137
Järvinen, T., see Raiman, J. **213**, 135
Järvinen, T., see Suihko, E. **215**, 137
Jenke, D.R., Evaluation of model solvent systems for assessing the accumulation of container extractables in drug formulations **224**, 51

Jie Li, C., see Obata, Y. **212**, 223
Johnston, T.P., L.B. Nguyen, W.A. Chu, S. Shefer, Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis **229**, 75
Johnston, T.P., see Alur, H.H. **212**, 171
Joiris, E., see Di Martino, P. **213**, 209
Jones, B.E., The filling of powders into two-piece hard capsules **227**, 5
Joshi, M., A. Misra, Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization **223**, 15
Jouyban-Gharamaleki, A., P. York, M. Hanna, B.J. Clark, Solubility prediction of salmeterol xinafoate in water–dioxane mixtures **216**, 33
Jóźwiak, Z., see Szwarocka, A. **220**, 43
Jørgensen, K., see Davidsen, J. **214**, 67
Jørgensen, K., see Kaasgaard, T. **214**, 63
Jørgensen, K., see Pedersen, T.B. **214**, 77
Jørgensen, K., see Vermehren, C. **214**, 93
Juárez, H., G. Rico, L. Villafuerte, Influence of admixed carboxymethylcellulose on release of 4-aminopyridine from hydroxypropyl methylcellulose matrix tablets **216**, 115
Junginger, H.E., see van den Bergh, B.A.I. **217**, 13
Jun, H.W., see Kang, L. **222**, 35
Jürjenson, H., see Nykänen, P. **229**, 155

Kaasgaard, T., O.G. Mouritsen, K. Jørgensen, Screening effect of PEG on avidin binding to liposome surface receptors **214**, 63
Kalia, Y.N., see Alberti, I. **219**, 11
Kalia, Y.N., see Moser, K. **224**, 169
Kallinteri, P., S. G. Antimisiaris, Solubility of drugs in the presence of gelatin: effect of drug lipophilicity and degree of ionization **221**, 219
Kaltenbach, M.L., see Hoizey, G. **229**, 147
Kamba, M., Y. Seta, A. Kusai, K. Nishimura, Evaluation of the mechanical destructive force in the stomach of dog **228**, 209
Kambia, K., T. Dine, R. Azar, B. Gressier, M. Luyckx, C. Brunet, Comparative study of the leachability of di(2-ethylhexyl) phthalate and tri(2-ethylhexyl) trimellitate from haemodialysis tubing **229**, 139
Kangas, M., see Kortesuo, P. **221**, 107
Kang, L., H.W. Jun, N. Mani, Preparation and characterization of two-phase melt systems of lidocaine **222**, 35
Kansu, E., see Eldem, T. **213**, 153
Kapsidou, T., I. Nikolakakis, S. Malamataris, Agglomeration state and migration of drugs in wet granulations during drying **227**, 97
Kapsi, S.G., J.W. Ayres, Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability **229**, 193
Karami, K., see Brounéus, F. **218**, 57
Katagai, K., see Nakamura, K. **218**, 93
Katare, O.P., see Agarwal, R. **228**, 43
Katayama, K., R. Matsui, T. Hatanaka, T. Koizumi, Effect of pH on skin permeation enhancement of acidic drugs by l-menthol-ethanol system **226**, 69
Kato, Y., H. Onishi, Y. Machida, Lactosaminated and intact *N*-succinyl-chitosans as drug carriers in liver metastasis **226**, 93
Katsura, M., see Ishikawa, F. **224**, 105
Kawasaki, N., see Miyazaki, S. **229**, 29
Kawasaki, N., see Miyazaki, S. **220**, 161
Kayser, O., A new approach for targeting to *Cryptosporidium parvum* using mucoadhesive nanosuspensions: research and applications **214**, 83
Kayser, O., see Gessner, A. **214**, 87
Kayser, O., see Jacobs, C. **214**, 3
Kazarian, S.G., see Raghavan, S.L. **221**, 95
Kellaway, I.W., see Darwis, Y. **215**, 113
Kelly, G., see Riley, R.G. **217**, 87
Kemper, M.S., see Patel, A.D. **212**, 295
Ketolainen, J., see Suihko, E. **217**, 225
Ketolainen, J., see Suihko, E. **215**, 137
Khaled, K.A., Y.A. Asiri, Y.M. El-Sayed, In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs **222**, 1
Khan, H., J.T. Fell, G.S. Macleod, The influence of additives on the spreading coefficient and adhesion of a film coating formulation to a model tablet surface **227**, 113
Khan, M.A., see Agarwal, V. **225**, 31
Khan, M.A., see Kommuru, T.R. **212**, 233
Khatri, L., K.M.G. Taylor, D.Q.M. Craig, K. Palin, An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions **227**, 121
Kholodova, E.A., see Kisel, M.A. **216**, 105
Khoo, C., see Broman, E. **222**, 139
Kiepfer, B., see Raghavan, S.L. **221**, 95
Kierstan, K.T.E., A.E. Beezer, J.C. Mitchell, J. Hadgraft, S.L. Raghavan, A.F. Davis, UV-spectrophotometry study of membrane transport processes with a novel diffusion cell **229**, 87
Kiesvaara, J., see Kortesuo, P. **221**, 107
Kiesvaara, J., see Rich, J. **212**, 121
Kikic, I., see Moneghini, M. **222**, 129
Kikuchi, M., see Nagase, Y. **229**, 163
Killen, B.U., O.I. Corrigan, Factors influencing drug release from stearic acid based compacts **228**, 189
Kim, C.-K., see Lee, E.-J. **218**, 125
Kim, C.-K., see Oh, H.-J. **212**, 63
Kim, C.-K., see Yong, C.S. **226**, 195
Kim, C.-K., Y.-Y. Hwang, J.Y. Chang, H.-G. Choi, S.-J. Lim, M.-K. Lee, Development of a novel dosage form for intramuscular injection of titrated extract of *Centella asiatica* in a mixed micellar system **220**, 141
Kim, C., see Choi, Y. **215**, 67
Kim, D.-D., see Kim, J.-E. **221**, 231
Kim, D.-D., see Kim, K.-E. **217**, 101
Kim, D.-D., see Kim, M.-K. **219**, 51
Kim, H.K., T.G. Park, Microencapsulation of dissociable human growth hormone aggregates within poly(D,L-lactic-co-glycolic acid) microparticles for sustained release **229**, 107

Kim, I.-S., S.-H. Kim, Evaluation of polymeric nanoparticles composed of cholic acid and methoxy poly(ethylene glycol) **226**, 23
Kim, K.-E., W.-J. Cho, S.-J. Chang, C.-S. Yong, C.-H. Lee, D.-D. Kim, Pharmacokinetics of a new antitumor 3-arylisoquinoline derivative, CWJ-a-5 **217**, 101
Kim, K.H., see Song, J.F. **212**, 153
Kim, K.-M., see Yong, C.S. **226**, 195
Kim, M.-K., H. Zhao, C.-H. Lee, D.-D. Kim, Formulation of a reservoir-type testosterone transdermal delivery system **219**, 51
Kim, N., see El-Kattan, A.F. **215**, 229
Kim, S.G., see Kim, Y.G. **229**, 45
Kim, S.H., see Choi, Y. **215**, 67
Kim, S.-H., see Kim, I.-S. **226**, 23
Kim, S.-R., see Kim, J.-E. **221**, 231
Kim, S.Y., see Choi, Y. **215**, 67
Kimura, K., see Yokogawa, K. **229**, 183
Kim, Y.G., M.K. Cho, J.W. Kwon, S.G. Kim, S.J. Chung, C.-K. Shim, M.G. Lee, Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein–calorie malnutrition **229**, 45
Kinget, R., see Maris, B. **213**, 143
Kinget, R., see Six, K. **213**, 163
Kinget, R., see Verheyen, S. **228**, 199
Kingzett, K., see Wu, H. **221**, 23
Kisel, M.A., L.N. Kulik, I.S. Tsybovsky, A.P. Vlasov, M.S. Vorob'yov, E.A. Kholodova, Z.V. Zabarovskaya, Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat **216**, 105
Kishimoto, J.-i., see Eaimtrakarn, S. **224**, 61
Kislalioglu, M.S., see Mehta, K.A. **213**, 7
Kissel, T., see Fischer, D. **225**, 97
Kiwada, H., see Huong, T.M. **215**, 197
Kiwada, H., see Ishida, T. **224**, 69
Klausegger, U., see Gabor, F. **221**, 35
Kleinebudde, P., see Tobiska, S. **224**, 141
Klimeš, J., J. Sochor, P. Doležal, J. Körner, HPLC evaluation of diclofenac in transdermal therapeutic preparations **217**, 153
Kmetec, V., see Špiclin, P. **222**, 271
Kobayashi, D., see Miyamoto, M. **226**, 127
Kobayashi, M., N. Sada, M. Sugawara, K. Iseki, K. Miyazaki, Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract **221**, 87
Kobayashi, M., see Fukui, E. **217**, 33
Kobayashi, M., see Fukui, E. **216**, 137
Kobayashi, M., see Murakami, H. **216**, 159
Kočevar, K., see Trojak, A. **218**, 145
Kohda-Shimizu, R., Y.-H. Li, Y. Shitara, K. Ito, Y. Tsuda, H. Yamada, T. Itoh, Oral absorption of cephalosporins is quantitatively predicted from in vitro uptake into intestinal brush border membrane vesicles **220**, 119
Koizumi, T., see Katayama, K. **226**, 69
Kojima, H., see Ishida, T. **224**, 69
Kokubo, S., see Yokota, S. **223**, 69
Kommuru, T.R., B. Gurley, M.A. Khan, I.K. Reddy, Self-emulsifying drug delivery systems (SEDDS) of coenzyme $Q_{10}$: formulation development and bioavailability assessment **212**, 233
Koopman, J.P., see van Oosterhout, Y.V.J.M. **221**, 175
Koosha, F., see Chidavaenzi, O.C. **216**, 43
Korhonen, M., L. Hellen, J. Hirvonen, J. Yliruusi, Rheological properties of creams with four different surfactant combinations - effect of storage time and conditions **221**, 187
Korhonen, O., see Suihko, E. **215**, 137
Körner, J., see Klimeš, J. **217**, 153
Kortesuo, P., M. Ahola, M. Kangas, A. Yli-Urpo, J. Kiesvaara, M. Marvola, In vitro release of dexmedetomidine from silica xerogel monoliths: effect of sol-gel synthesis parameters **221**, 107
Kortesuo, P., see Rich, J. **212**, 121
Kotsilkova, R., see Michailova, V. **222**, 7
Kowalczyk, A., see Szwarocka, A. **220**, 43
Kozjek, F., see Antolič, G. **215**, 147
Kranz, H., G.A. Brazeau, J. Napaporn, R.L. Martin, W. Millard, R. Bodmeier, Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems **212**, 11
Krause, K.P., R.H. Müller, Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation **214**, 21
Krause, K.P., R.H. Müller, Production of aqueous shellac dispersions by high pressure homogenisation **223**, 89
Krishna, G., K.-j. Chen, C.-c. Lin, A.A. Nomeir, Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2 **222**, 77
Kristensen, H.G., see Christensen, K.L. **212**, 187
Kristensen, H.G., see Christensen, K.L. **212**, 195
Kristensen, H.G., see Nielsen, P.B. **222**, 217
Kriwet, K., see Moser, K. **224**, 169
Krusteva, E., see Michailova, V. **222**, 7
Kubo, W., see Miyazaki, S. **220**, 161
Kulik, L.N., see Kisel, M.A. **216**, 105
Kumar, V., see Zhu, L. **223**, 35
Kumria, R., see Sinha, V.R. **224**, 19
Kusai, A., see Kamba, M. **228**, 209
Kuselman, I., see Weisman, A. **221**, 159
Kwon, J.W., see Kim, Y.G. **229**, 45

Lacey, L.F., see Basit, A.W. **227**, 157
Lahorte, P., see De Kerf, M. **221**, 69
Laine, E., see Mellin, V. **220**, 85
Laine, E., see Suihko, E. **217**, 225
Laine, E., see Suihko, E. **215**, 137
Lambert, G., E. Fattal, H. Pinto-Alphandary, A. Gulik, P. Couvreur, Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides **214**, 13
Lambov, N., see Yoncheva, K. **226**, 31
Lameiro, M.H., see Pinto, J.F. **227**, 71
Lamiable, D., see Hoizey, G. **229**, 147
Lane, M., see McCargar, L. **222**, 191
Larsen, C., see Larsen, S.W. **230**, 67

Larsen, C., see Larsen, S.W. **216**, 83
Larsen, S.W., A.E. Thomsen, E. Rinvar, G.J. Friis, C. Larsen, Effect of drug lipophilicity on in vitro release rate from oil vehicles using nicotinic acid esters as model prodrug derivatives **216**, 83
Larsen, S.W., E. Rinvar, O. Svendsen, J. Lykkesfeldt, G.J. Friis, C. Larsen, Determination of the disappearance rate of iodine-125 labelled oils from the injection site after intramuscular and subcutaneous administration to pigs **230**, 67
Latham, R., see Reason, M. **222**, 121
Latrofa, A., see Franco, M. **225**, 63
Lau-Cam, C.A., see Song, J.F. **212**, 153
Lebas, G., see Boudad, H. **218**, 113
Leclerc, B., see Sommier, N. **222**, 243
Ledger, R., see Walker, G.F. **216**, 77
Lee, C.H., A. Singla, Y. Lee, Biomedical applications of collagen **221**, 1
Lee, C.-H., see Kim, J.-E. **221**, 231
Lee, C.-H., see Kim, K.-E. **217**, 101
Lee, C.-H., see Kim, M.-K. **219**, 51
Lee, E.-J., S.-W. Lee, H.-G. Choi, C.-K. Kim, Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate–dextrin based solid microspheres **218**, 125
Lee, K.-S., see Choi, Y. **215**, 67
Lee, M.G., see Kim, Y.G. **229**, 45
Lee, M.-K., see Kim, C.-K. **220**, 141
Lee, S.-H., see Kim, J.-E. **221**, 231
Lee, S.-W., see Lee, E.-J. **218**, 125
Lee, Y.-J., S.-J. Chung, C.-K. Shim, The prevention of cyclosporin A adsorption to Transwell® surfaces by human plasma **224**, 201
Lee, Y., see Lee, C.H. **221**, 1
Legrand, P., see Boudad, H. **218**, 113
Leharne, S.A., see Armstrong, J.K. **229**, 57
Lehman, P.A., see Viegas, T.X. **219**, 73
Lehto, V.-P., see Suihko, E. **217**, 225
Lempää, S., see Nykänen, P. **229**, 155
Leuenberger, H., see Stengele, A. **225**, 123
Levis, S.R., P.B. Deasy, Pharmaceutical applications of size reduced grades of surfactant co-processed microcrystalline cellulose **230**, 25
Levis, S.R., P.B. Deasy, Production and evaluation of size reduced grades of microcrystalline cellulose **213**, 13
Levy, R.J., see Ciftci, K. **218**, 81
Lewandowski, W., see Szachowicz-Petelska, B. **222**, 169
Ley, R.W., see Brown, J.R. **213**, 127
Liang, C.-C., see Tsai, T.-H. **216**, 61
Liesenfeld, O., see Schöler, N. **221**, 57
Liggins, R.T., H.M. Burt, Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers **222**, 19
Lim, S.-J., see Kim, C.-K. **220**, 141
Lim, S.-J., see Yong, C.S. **226**, 195
Lin, C.-c., see Krishna, G. **222**, 77
Lindhardt, K., M. Bagger, K.H. Andreasen, E. Bechgaard, Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man **217**, 121
Lippacher, A., R.H. Müller, K. Mäder, Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles **214**, 9
Lippold, B.C., see Freichel, O.L. **216**, 165
Lippold, B.C., see Zuleger, S. **217**, 139
Liso, G., see Franco, M. **225**, 63
Liu, H., see Pan, X. **220**, 33
Liu, Y.-Z., see Chung, T.-W. **212**, 161
Livaniou, E., see Panagi, Z. **221**, 143
Li, Y.-H., see Kohda-Shimizu, R. **220**, 119
Li, Y., see Mitra, R. **217**, 25
Li, Z., see Perkins, A.C. **222**, 295
Loebis, A.E., see Stenekes, R.J.H. **214**, 17
Loftsson, T., H. Guðmundsdóttir, J.F. Sigurjónsdóttir, H.H. Sigurðsson, S.D. Sigfússon, M. Másson, E. Stefánsson, Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray **212**, 29
Loftsson, T., M. Masson, Cyclodextrins in topical drug formulations: theory and practice **225**, 15
Lopez-Galindo, A., see Viseras, C. **217**, 201
López-Solís, J., L. Villafuerte-Robles, Effect of disintegrants with different hygroscopicity on dissolution of Norfloxacin/Pharmatose DCL 11 tablets **216**, 127
Loukas, Y.L., Quantitative structure-binding relationships (QSBR) and artificial neural networks: improved predictions in drug: cyclodextrin inclusion complexes **226**, 207
Lovrek, M., see Zovko, M. **228**, 129
Łubgan, D., see Szwarocka, A. **220**, 43
Luner, P.E., D. VanDer Kamp, Wetting characteristics of media emulating gastric fluids **212**, 81
Luner, P.E., see Patel, A.D. **212**, 295
Luukkonen, P., J.M. Newton, F. Podczeck, J. Yliruusi, Use of a capillary rheometer to evaluate the rheological properties of microcrystalline cellulose and silicified microcrystalline cellulose wet masses **216**, 147
Luyckx, M., see Kambia, K. **229**, 139
Lykkesfeldt, J., see Larsen, S.W. **230**, 67

Mabuchi, H., see Yokogawa, K. **229**, 183
Macfarlane, C.B., Drugs in Pharmaceutical Sciences, Volume 86, Pharmaceutical Project Management: Edited by Tony Kennedy. ISBN 0-8247-0111-9 **224**, 205
Machet, L., see Boucaud, A. **228**, 69
Machet, M.C., see Boucaud, A. **228**, 69
Machida, M., see Sugano, K. **228**, 181
Machida, Y., see Kato, Y. **226**, 93
Machida, Y., see Tokumura, T. **228**, 1
Mackay, K.M.B., A.C. Williams, B.W. Barry, Effect of melting point of chiral terpenes on human stratum corneum uptake **228**, 89
Macleod, G.S., see Khan, H. **227**, 113
Mäder, K., see Lippacher, A. **214**, 9
Maitani, Y., see Junping, W. **219**, 183
Maitani, Y., see Ungphaiboon, S. **220**, 111
Malamataris, S., see Kapsidou, T. **227**, 97
Malick, A.W., see Mehta, K.A. **213**, 7
Mani, N., see Kang, L. **222**, 35

Mantovani, V.E., see Collado, M.S. **229**, 205
Marchetti, J.M., see Netz, D.J.A. **213**, 117
Mariappan, T.T., see Singh, S. **228**, 5
Marini, A., see Berbenni, V. **221**, 123
Maris, B., L. Verheyden, K. Van Reeth, C. Samyn, P. Augustijns, R. Kinget, G. Van den Mooter, Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting **213**, 143
Marriott, C., see Zeng, X.M. **218**, 63
Marsaud, V., see Brigger, I. **214**, 37
Marshall, K., see DeCrosta, M.T. **213**, 45
Martelli, S., see Di Martino, P. **213**, 209
Martin, G.P., see Brown, M.B. **225**, 113
Martin, G.P., see Zeng, X.M. **218**, 63
Martin, R.L., see Kranz, H. **212**, 11
Martins, P., see Pinto, J.F. **227**, 71
Martínez-Miranda, L.J., see Nair, R. **225**, 83
Marton, S., see Farkas, E. **213**, 1
Marvola, M., see Kortesuo, P. **221**, 107
Marvola, M., see Nykänen, P. **229**, 155
Massart, D.L., see Adams, E. **226**, 107
Massart, D.L., see Adams, E. **212**, 41
Massart, D.L., see Rambali, B. **220**, 129
Massart, D.L., see Rambali, B. **220**, 149
Masson, M., see Loftsson, T. **225**, 15
Másson, M., see Loftsson, T. **212**, 29
Matsui, R., see Katayama, K. **226**, 69
Matsumoto, M., see Fujii, M. **222**, 57
Matsushita, R., see Yokogawa, K. **229**, 183
Mattsson, M.S., see Hedenus, P. **224**, 207
Mavon, A., see Boucaud, A. **228**, 69
Mazzi, G., see Bilia, A.R. **213**, 199
McCargar, L., D. Crail, R. Dansereau, W. Myers, M. Lane, The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans **222**, 191
McClure, A.F., see Gebauer, M.G. **223**, 49
Medina, J., A. Salvadó, A. del Pozo, Use of ultrasound to prepare lipid emulsions of lorazepam for intravenous injection **216**, 1
Meeten, G.H., see Viseras, C. **217**, 201
Mehta, K.A., M.S. Kislalioglu, W. Phuapradit, A.W. Malick, N.H. Shah, Release performance of a poorly soluble drug from a novel, Eudragit®-based multi-unit erosion matrix **213**, 7
Mehvar, R., see Zhang, X. **229**, 173
Meingassner, J.G., see Schmook, F.P. **215**, 51
Mellin, V., J. Salonen, E. Laine, The stimulated acoustic relaxation emission of maize starch tablets **220**, 85
Merino, S., see Vázquez, J.L. **220**, 53
Merkle, H.P., see Pálinkó-Biró, E. **221**, 153
Micard, S., A. Rieutord, P. Prognon, M. Hassan, F. Brion, Stability and sterility of meglumine gadoterate injection repackaged in plastic syringes **212**, 93
Michael, Y., M.J. Snowden, B.Z. Chowdhry, I.C. Ashurst, C.J. Davies-Cutting, T. Riley, Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system **221**, 165
Michailova, V., S. Titeva, R. Kotsilkova, E. Krusteva, E. Minkov, Influence of hydrogel structure on the processes of water penetration and drug release from mixed hydroxypropylmethyl cellulose/thermally pregelatinized waxy maize starch hydrophilic matrices **222**, 7
Michel, L., see Vignardet, C. **224**, 115
Michniak, B.B., see El-Kattan, A.F. **215**, 229
Millard, W., see Kranz, H. **212**, 11
Millart, H., see Hoizey, G. **229**, 147
Millet, J., see Vignardet, C. **224**, 115
Miloshev, S., see Yoncheva, K. **226**, 31
Minkov, E., see Michailova, V. **222**, 7
Misra, A., see Joshi, M. **223**, 15
Mitchell, J.C., see Kierstan, K.T.E. **229**, 87
Mitchell, J.C., see Zaman, F. **227**, 133
Mitchell, J.C., see Zaman, F. **225**, 135
Mitra, A.K., see Alur, H.H. **212**, 171
Mitra, A.K., see Mitra, R. **217**, 25
Mitra, R., I. Pezron, Y. Li, A.K. Mitra, Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids **217**, 25
Miyamoto, K.-i., see Yokogawa, K. **229**, 183
Miyamoto, M., H. Natsume, I. Satoh, K. Ohtake, M. Yamaguchi, D. Kobayashi, K. Sugibayashi, Y. Morimoto, Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats **226**, 127
Miyamura, N., see Fukui, E. **217**, 33
Miyamura, N., see Fukui, E. **216**, 137
Miyazaki, K., see Kobayashi, M. **221**, 87
Miyazaki, S., N. Kawasaki, W. Kubo, K. Endo, D. Attwood, Comparison of in situ gelling formulations for the oral delivery of cimetidine **220**, 161
Miyazaki, S., S. Suzuki, N. Kawasaki, K. Endo, A. Takahashi, D. Attwood, In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride **229**, 29
Mocanu, G., see Fundueanu, G. **218**, 13
Moës, A.J., see Eeckman, F. **222**, 259
Moisan, M., J. Barbeau, S. Moreau, J. Pelletier, M. Tabrizian, L.H. Yahia, Low-temperature sterilization using gas plasmas: a review of the experiments and an analysis of the inactivation mechanisms **226**, 1
Molema, J., see Broeders, M.E.A.C. **228**, 219
Molina-Díaz, A., see Ruiz-Medina, A. **216**, 95
Momose, Y., see Yamamura, S. **212**, 203
Mondelaers, W., see De Kerf, M. **221**, 69
Moneghini, M., I. Kikic, D. Voinovich, B. Perissutti, J. Filipović-Grčić, Processing of carbamazepine–PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution **222**, 129
Mönkkönen, J., see Raiman, J. **213**, 135
Monteiro, J., see Bettencourt, A. **219**, 89
Montero, M.T., see Vázquez, J.L. **220**, 53
Monti, D., R. Giannelli, P. Chetoni, S. Burgalassi, Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro **229**, 131

Montisci, M.-J., G. Giovannuci, D. Duchêne, G. Ponchel, Covalent coupling of asparagus pea and tomato lectins to poly(lactide) microspheres **215**, 153
Morana, A., A.D. Rosa, M. Carteni, M. Parlato, M.D. Rosa, *S*-adenosyl-L-methionine *N*-ole-1-oyltaurate: pharmacokinetic of the orally administered salt in rats **230**, 47
Moreau, S., see Moisan, M. **226**, 1
Morgenni, F., see Bilia, A.R. **213**, 199
Mori, K., see Nakamura, K. **218**, 93
Mori, K., see Sugibayashi, K. **219**, 107
Morimoto, Y., see Miyamoto, M. **226**, 127
Morishita, M., J.M. Barichello, K. Takayama, Y. Chiba, S. Tokiwa, T. Nagai, Pluronic® F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin **212**, 289
Morita, T., Y. Horikiri, T. Suzuki, H. Yoshino, Preparation of gelatin microparticles by co-lyophilization with poly(ethylene glycol): characterization and application to entrapment into biodegradable microspheres **219**, 127
Moser, K., K. Kriwet, Y.N. Kalia, R.H. Guy, Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery **224**, 169
Moulik, S.P., see Acharya, A. **229**, 213
Mouritsen, O.G., see Davidsen, J. **214**, 67
Mouritsen, O.G., see Kaasgaard, T. **214**, 63
Mouritsen, O.G., see Pedersen, T.B. **214**, 77
Mrhar, A., see Burjak, M. **224**, 123
Muggironi, M., see Franco, M. **225**, 63
Mulinacci, N., A. Romani, P. Pinelli, S. Gallori, C. Giaccherini, F.F. Vincieri, Stabilisation of natural anthocyanins by micellar Systems **216**, 23
Müller, R.H., see Gessner, A. **214**, 87
Müller, R.H., see Jacobs, C. **214**, 3
Müller, R.H., see Krause, K.P. **223**, 89
Müller, R.H., see Krause, K.P. **214**, 21
Müller, R.H., see Lippacher, A. **214**, 9
Müller, R.H., see Schöler, N. **221**, 57
Müllertz, A., see Nielsen, P.B. **222**, 217
Murai, M., see Yokota, S. **223**, 69
Murakami, H., T. Yoneyama, K. Nakajima, M. Kobayashi, Correlation between loose density and compactibility of granules prepared by various granulation methods **216**, 159
Muševič, I., see Trojak, A. **218**, 145
Myers, W., see McCargar, L. **222**, 191

Nagai, T., see Junping, W. **219**, 183
Nagai, T., see Morishita, M. **212**, 289
Nagai, T., see Obata, Y. **212**, 223
Nagai, T., see Zhang, Q. **218**, 75
Nagase, Y., M. Hirata, K. Wada, H. Arima, F. Hirayama, T. Irie, M. Kikuchi, K. Uekama, Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin **229**, 163
Naggar, V.F., see El-Kamel, A.H. **220**, 13
Naik, A., see Alberti, I. **219**, 11
Nair, R., N. Nyamweya, S. Gönen, L.J. Martínez-Miranda, S.W. Hoag, Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation **225**, 83
Najib, N.M., see Gabboun, N.H. **212**, 73
Nakaharu, T., see Yokogawa, K. **229**, 183
Nakajima, K., see Murakami, H. **216**, 159
Nakamichi, K., H. Yasuura, H. Fukui, M. Oka, S. Izumi, Evaluation of a floating dosage form of nicardipine hydrochloride and hydroxypropylmethylcellulose acetate succinate prepared using a twin-screw extruder **218**, 103
Nakamura, K., K. Katagai, K. Mori, N. Higo, S. Sato, K. Yamamoto, Transdermal administration of salmon calcitonin by pulse depolarization-iontophoresis in rats **218**, 93
Nakamura, K., T. Tanaka, K. Saito, S. Yokohama, T. Sonobe, Stabilization of minodronic acid in aqueous solution for parenteral formulation **222**, 91
Nakano, T., H. Yuasa, Suppression of agglomeration in fluidized bed coating. IV. Effects of sodium citrate concentration on the suppression of particle agglomeration and the physical properties of HPMC film **215**, 3
Nakashima, E., see Yokogawa, K. **229**, 183
Napaporn, J., see Kranz, H. **212**, 11
Narayan, C.P.S., see Sreenivasa Rao, B. **230**, 1
Nastruzzi, C., see Fundueanu, G. **218**, 13
Natsume, H., see Miyamoto, M. **226**, 127
Nazzal, S., Y. Wang, Characterization of soft gelatin capsules by thermal analysis **230**, 35
Nehne, J., see Driscoll, D.F. **219**, 21
Netz, D.J.A., P. Sepulveda, V.C. Pandolfelli, A.C.C. Spadaro, J.B. Alencastre, M.V.L.B. Bentley, J.M. Marchetti, Potential use of gelcasting hydroxyapatite porous ceramic as an implantable drug delivery system **213**, 117
Newell, H.E., G. Buckton, D.A. Butler, F. Thielmann, D.R. Williams, The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallisation **217**, 45
Newton, J.M., see Luukkonen, P. **216**, 147
Newton, J.M., see Tomer, G. **217**, 237
Nguyen, L.B., see Johnston, T.P. **229**, 75
Nicoli, S., P. Santi, P. Couvreur, G. Couarraze, P. Colombo, E. Fattal, Design of triptorelin loaded nanospheres for transdermal iontophoretic administration **214**, 31
Nielsen, P.B., A. Müllertz, T. Norling, H.G. Kristensen, The effect of α-tocopherol on the in vitro solubilisation of lipophilic drugs **222**, 217
Niemann, W., see Driscoll, D.F. **219**, 21
Niemi, R., see Raiman, J. **213**, 135
Niklasson, G.A., see Hedenus, P. **224**, 207
Nikolakakis, I., see Kapsidou, T. **227**, 97
Ni, N., M. Tesconi, S.E. Tabibi, S. Gupta, S.H. Yalkowsky, Use of pure *t*-butanol as a solvent for freeze-drying: a case study **226**, 39
Nisbet, M., see Zaman, F. **225**, 135
Nishimura, K., see Kamba, M. **228**, 209
Niu, G., see Pan, X. **220**, 33
Nokhodchi, A., see Shokri, J. **228**, 99

Nomeir, A.A., see Krishna, G. **222**, 77
Norling, T., see Nielsen, P.B. **222**, 217
Nowak, M., see Valenta, C. **217**, 79
Nowbakht, P., see Betz, G. **228**, 147
Nozaki, K., see Yokota, S. **223**, 69
Nyamweya, N., see Nair, R. **225**, 83
Nykänen, P., S. Lempää, M.-L. Aaltonen, H. Jürjenson, P. Veski, M. Marvola, Citric acid as excipient in multiple-unit enteric-coated tablets for targeting drugs on the colon **229**, 155

Obata, Y., C. Jie Li, M. Fujikawa, K. Takayama, H. Sato, K. Higashiyama, K. Isowa, T. Nagai, Evaluation and structure–activity relationship of synthesized cyclohexanol derivatives on percutaneous absorption of ketoprofen using artificial neural network **212**, 223
O'Connor, K.M., O.I. Corrigan, Comparison of the physicochemical properties of the *N*-(2-hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac **222**, 281
O'Connor, K.M., O.I. Corrigan, Preparation and characterisation of a range of diclofenac salts **226**, 163
Ofori-Kwakye, K., J.T. Fell, Biphasic drug release: the permeability of films containing pectin, chitosan and HPMC **226**, 139
Oh, H.-J., Y.-K. Oh, C.-K. Kim, Effects of vehicles and enhancers on transdermal delivery of melatonin **212**, 63
Oh, I.-J., see Shin, S.-C. **222**, 199
Oh, P.-S., see Yong, C.S. **226**, 195
Ohtake, K., see Miyamoto, M. **226**, 127
Oh, Y.-K., see Oh, H.-J. **212**, 63
Okamoto, H., see Todo, H. **220**, 101
Oka, M., see Nakamichi, K. **218**, 103
Olbrich, C., see Gessner, A. **214**, 87
Olbrich, C., see Schöler, N. **221**, 57
Oliveira, A.G., see Dalmora, M.E. **222**, 45
Olivier, J.-C., M. Djilani, S. Fahmy, W. Couet, In situ nasal absorption of midazolam in rats **213**, 187
Onishi, H., see Kato, Y. **226**, 93
Orafidiya, L.O., A.O. Oyedele, A.O. Shittu, A.A. Elujoba, The formulation of an effective topical antibacterial product containing *Ocimum gratissimum* leaf essential oil **224**, 177
Ortega-Barrales, P., see Ruiz-Medina, A. **216**, 95
Oussoren, C., G. Storm, Preface **214**, 1
Oussoren, C., see Verbaan, F.J. **214**, 99
Owens, M.D., G. Baillie, G.W. Halbert, Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences **228**, 109
Oyedele, A.O., see Orafidiya, L.O. **224**, 177
Ozaki, E., see Yokogawa, K. **229**, 183

Pálinkó-Biró, E., G. Rónaszéki, H.P. Merkle, B. Gander, Release kinetics and immunogenicity of parvovirus microencapsulated in PLA/PLGA microspheres **221**, 153
Palin, K., see Khatri, L. **227**, 121
Palmieri, G.F., see Di Martino, P. **213**, 209
Panagi, Z., A. Beletsi, G. Evangelatos, E. Livaniou, D.S. Ithakissios, K. Avgoustakis, Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles **221**, 143
Panchagnula, R., P.S. Salve, N.S. Thomas, A.K. Jain, P. Ramarao, Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin **219**, 95
Pandolfelli, V.C., see Netz, D.J.A. **213**, 117
Pan, X., H. Liu, Z. An, J. Wang, G. Niu, Microwave-enhanced dehydration and solvent washing purification of penicillin G sulfoxide **220**, 33
Pardha Saradhi, S.V., see Sreenivasa Rao, B. **230**, 1
Park, E.-S., see Rhee, Y.-S. **228**, 161
Park, T.G., see Kim, H.K. **229**, 107
Parlato, M., see Morana, A. **230**, 47
Paronen, P., see Suihko, E. **217**, 225
Paronen, P., see Suihko, E. **215**, 137
Patat, F., see Boucaud, A. **228**, 69
Patel, N.V., see Sakthivel, T. **214**, 43
Pavelić, Ž., N. Škalko-Basnet, R. Schubert, Liposomal gels for vaginal drug delivery **219**, 139
Pedersen, G.P., see Christensen, K.L. **212**, 187
Pedersen, G.P., see Christensen, K.L. **212**, 195
Pedersen, H., see Bjerregaard, S. **215**, 13
Pedersen, T.B., M.C. Sabra, S. Frokjaer, O.G. Mouritsen, K. Jørgensen, Association of an acylated model peptide with DPPC–DPPS lipid membranes **214**, 77
Peeters, J., see Six, K. **213**, 163
Peinhardt, G., M. Wiese, Microionization constants: novel approach for the determination of the zwitterionic equilibrium of hydroxyphenylalkylamines by photometric titration **215**, 83
Peira, E., P. Scolari, M.R. Gasco, Transdermal permeation of apomorphine through hairless mouse skin from microemulsions **226**, 47
Pelletier, J., see Moisan, M. **226**, 1
Perez Cullel, N., see Couteau, C. **222**, 153
Perioli, L., see Ambrogi, V. **220**, 23
Perissutti, B., see Moneghini, M. **222**, 129
Perkins, A.C., C.G. Wilson, M. Frier, P.E. Blackshaw, R.J. Dansereau, R.M. Vincent, D. Wenderoth, S. Hathaway, Z. Li, R.C. Spiller, The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water **222**, 295
Perkins, A.C., see Jackson, S.J. **212**, 55
Perumal, D., Microencapsulation of ibuprofen and Eudragit® RS 100 by the emulsion solvent diffusion technique **218**, 1
Pezron, I., see Mitra, R. **217**, 25
Phuapradit, W., see Mehta, K.A. **213**, 7
Pignatello, R., M. Ferro, G. De Guidi, G. Salemi, M.A. Vandelli, S. Guccione, M. Geppi, C. Forte, G. Puglisi, Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100® and RL100® **218**, 27

Pinelli, P., see Mulinacci, N. **216**, 23
Piñeyro-López, A., see Caballero-Quintero, A. **229**, 23
Ping, Q., see Guo, J. **216**, 17
Pinney, R.J., see Wickens, H.J. **227**, 149
Pinto-Alphandary, H., see Lambert, G. **214**, 13
Pinto, J.F., M.H. Lameiro, P. Martins, Investigation on the co-extrudability and spheronization properties of wet masses **227**, 71
Planinšek, O., A. Trojak, S. Srčič, The dispersive component of the surface free energy of powders assessed using inverse gas chromatography and contact angle measurements **221**, 211
Podczeck, F., see Luukkonen, P. **216**, 147
Podczeck, F., see Tomer, G. **217**, 237
Podczeck, F., The determination of fracture mechanics properties of pharmaceutical materials in mode III loading using an anti-clastic plate bending method **227**, 39
Podczeck, F., The end of a marathon? **227**, 1
Polli, J.E., see Tajarobi, F. **215**, 263
Polli, J., see Gharat, L. **219**, 1
Ponchel, G., see Boudad, H. **218**, 113
Ponchel, G., see Montisci, M.-J. **215**, 153
Porion, P., see Sommier, N. **222**, 243
Porteous, P., see Reason, M. **222**, 121
Pourcelot, Y., see Andrès, C. **218**, 153
Pourcelot, Y., see Di Martino, P. **213**, 209
Pourcelot, Y., see Tromelin, A. **224**, 131
Prabhu, S., A.I. Jacknowitz, P.J. Stout, A study of factors controlling dissolution kinetics of zinc complexed protein suspensions in various ionic species **217**, 71
Prasad, K.V.R., R.I. Ristic, D.B. Sheen, J.N. Sherwood, Crystallization of paracetamol from solution in the presence and absence of impurity **215**, 29
Preijers, F.W.M.B., see van Oosterhout, Y.V.J.M. **221**, 175
Price, J.C., see Gupta, V.K. **213**, 93
Price, J.C., see Gupta, V.K. **213**, 83
Primožič, S., see Antolič, G. **215**, 147
Prinsen, M.G., see Hinrichs, W.L.J. **215**, 163
Prognon, P., see Micard, S. **212**, 93
Provenzano, M.R., see Franco, M. **225**, 63
Puglia, C., F. Bonina, G. Trapani, M. Franco, M. Ricci, Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations **228**, 79
Puglisi, G., see Pignatello, R. **218**, 27
Purohit, G., T. Sakthivel, A.T. Florence, Interaction of cationic partial dendrimers with charged and neutral liposomes **214**, 71

Qiu, L.Y., K.J. Zhu, Design of a core-shelled polymer cylinder for potential programmable drug delivery **219**, 151
Quan, Q.-Z., see Yong, C.S. **226**, 195

Rácz, I., see Farkas, E. **213**, 1
Rades, T., see Forster, A. **226**, 147
Radwan, M.A., H.Y. Aboul-Enein, The effect of absorption enhancers on the initial degradation kinetics of insulin by α-chymotrypsin **217**, 111
Raghavan, C.V., V.D. Abimon, Intranasal delivery of tenoxicam in rat **221**, 227
Raghavan, S.L., A. Trividic, A.F. Davis, J. Hadgraft, Crystallization of hydrocortisone acetate: influence of polymers **212**, 213
Raghavan, S.L., B. Kiepfer, A.F. Davis, S.G. Kazarian, J. Hadgraft, Membrane transport of hydrocortisone acetate from supersaturated solutions: the role of polymers **221**, 95
Raghavan, S.L., see Dias, M. **216**, 51
Raghavan, S.L., see Iervolino, M. **212**, 131
Raghavan, S.L., see Kierstan, K.T.E. **229**, 87
Raiman, J., R. Niemi, J. Vepsäläinen, K. Yritys, T. Järvinen, J. Mönkkönen, Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells **213**, 135
Ramachandran, C., see Wu, H. **221**, 23
Ramachandran, C., see Wu, H. **220**, 63
Ramana Murthy, K.V., see Sreenivasa Rao, B. **230**, 1
Ramarao, P., see Panchagnula, R. **219**, 95
Rambali, B., L. Baert, D.L. Massart, Using experimental design to optimize the process parameters in fluidized bed granulation on a semi-full scale **220**, 149
Rambali, B., L. Baert, E. Jans, D.L. Massart, Influence of the roll compactor parameter settings and the compression pressure on the buccal bio-adhesive tablet properties **220**, 129
Rastogi, S.K., J. Singh, Lipid extraction and iontophoretic transport of leuprolide acetate through porcine epidermis **215**, 241
Rastogi, S.K., J. Singh, Lipid extraction and transport of hydrophilic solutes through porcine epidermis **225**, 75
Rathod, I.S., see Shishoo, C.J. **228**, 53
Ravi Kumar, N., see Sreenivasa Rao, B. **230**, 1
Reason, M., P. Teesdale-Spittle, R. Latham, G. Dawson, P. Porteous, G. Smith, A TSM sensor investigation of low crystallinity cellulose films **222**, 121
Reddy, I.K., see Agarwal, V. **225**, 31
Reddy, I.K., see Kommuru, T.R. **212**, 233
Rege, B.D., see Tajarobi, F. **215**, 263
Rege, B., see Gharat, L. **219**, 1
Reithmeier, H., J. Herrmann, A. Göpferich, Development and characterization of lipid microparticles as a drug carrier for somatostatin **218**, 133
Remon, J.P., see De Kerf, M. **221**, 69
Remon, J.P., see Vergote, G.J. **219**, 81
Renoir, M., see Brigger, I. **214**, 37
Rey, S., see Stengele, A. **225**, 123
Rhee, J.-D., see Yong, C.S. **226**, 195
Rhee, Y.-S., J.-G. Choi, E.-S. Park, S.-C. Chi, Transdermal delivery of ketoprofen using microemulsions **228**, 161
Rhem, R., see Dubus, J.-C. **222**, 101
Ricci, M., see Puglia, C. **228**, 79
Rich, J., P. Kortesuo, M. Ahola, A. Yli-Urpo, J. Kiesvaara, J. Seppälä, Effect of the molecular weight of poly(ε-caprolactone-co-DL-lactide) on toremifene citrate release from copolymer/silica xerogel composites **212**, 121

Rico, G., see Juárez, H. **216**, 115
Rico, J.M.T., see Bettencourt, A. **219**, 89
Rieutord, A., see Micard, S. **212**, 93
Riley, R.G., J.D. Smart, J. Tsibouklis, P.W. Dettmar, F. Hampson, J.A. Davis, G. Kelly, W.R. Wilber, An investigation of mucus/polymer rheological synergism using synthesised and characterised poly(acrylic acid)s **217**, 87
Riley, T., see Michael, Y. **221**, 165
Rinvar, E., see Larsen, S.W. **230**, 67
Rinvar, E., see Larsen, S.W. **216**, 83
Ristic, R.I., see Prasad, K.V.R. **215**, 29
Rivasi, F., see Vandelli, M.A. **215**, 175
Robles, J.C., see Collado, M.S. **229**, 205
Rodrigues, C.A., see Bürger, C. **223**, 29
Roessler, B.J., see Wu, H. **221**, 23
Roessler, B.J., see Wu, H. **220**, 63
Rohmer, A.-C., see Vaugelade, C. **229**, 67
Romani, A., see Mulinacci, N. **216**, 23
Rónaszéki, G., see Pálinkó-Bíró, E. **221**, 153
Rosa, A.D., see Morana, A. **230**, 47
Rosa, M.D., see Morana, A. **230**, 47
Rowley, G., Quantifying electrostatic interactions in pharmaceutical solid systems **227**, 47
Ruddy, S., see Vergote, G.J. **219**, 81
Ruiter, D.J., see van Oosterhout, Y.V.J.M. **221**, 175
Ruiz-Medina, A., M.L. Fernández-de Córdova, P. Ortega-Barrales, A. Molina-Díaz, Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic acid in pharmaceutical preparations **216**, 95

Sabés, M., see Barnadas-Rodríguez, R. **213**, 175
Sabir, A., B. Evans, S. Jain, Formulation and process optimization to eliminate picking from market image tablets **215**, 123
Sabra, M.C., see Pedersen, T.B. **214**, 77
Sachse, A., see Berger, N. **223**, 55
Sada, N., see Kobayashi, M. **221**, 87
Sadiq, L., see Uchegbu, I.F. **230**, 77
Sadiq, L., see Uchegbu, I.F. **224**, 185
Saettone, M.F., see Di Colo, G. **220**, 169
Saettone, M.F., see Di Colo, G. **215**, 101
Saitoh, K., see Sugano, K. **228**, 181
Saito, K., see Nakamura, K. **222**, 91
Sakr, A., see Allinson, J.G. **221**, 49
Sakthivel, T., see Purohit, G. **214**, 71
Sakthivel, T., see Yanai, S. **214**, 49
Sakthivel, T., V. Jaitely, N.V. Patel, A.T. Florence, Non-aqueous emulsions: hydrocarbon–formamide systems **214**, 43
Salemi, G., see Pignatello, R. **218**, 27
Salonen, J., see Mellin, V. **220**, 85
Salvadó, A., see Medina, J. **216**, 1
Salve, P.S., see Panchagnula, R. **219**, 95
Samyn, C., see Maris, B. **213**, 143
Sánchez, A., see De Campos, A.M. **224**, 159
Sandri, S., see Bürger, C. **223**, 29
Santi, P., see Nicoli, S. **214**, 31
Santoyo, S., see de Jalón, E.G. **226**, 181
Santoyo, S., see Doliwa, A. **229**, 37
Sanyal, S.K., see Acharya, A. **229**, 213
Sarbolouki, M.N., see Elmi, M.M. **215**, 45
Sarda, N., see Singh, S. **228**, 5
Satoh, I., see Miyamoto, M. **226**, 127
Sato, H., see Obata, Y. **212**, 223
Sato, S., see Nakamura, K. **218**, 93
Savale, S.S., see Shishoo, C.J. **228**, 53
Savaş, H., O. Güven, Investigation of active substance release from poly(ethylene oxide) hydrogels **224**, 151
Saville, D.J., Influence of storage on in-vitro release of ibuprofen from sugar coated tablets **224**, 39
Schattenberg, A.V.M.B., see van Oosterhout, Y.V.J.M. **221**, 175
Schätzleinä, A.G., see Uchegbu, I.F. **230**, 77
Schätzleinä, A.G., see Uchegbu, I.F. **224**, 185
Schätzlein, A.G., see Brown, M.D. **229**, 1
Schawe, J.E.K., see Schubnell, M. **217**, 173
Schiffelers, R.M., G. Storm, I.A.J.M. Bakker-Woudenberg, Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models **214**, 103
Schiffelers, R., see Vermehren, C. **214**, 93
Schmidt, C., R. Bodmeier, A multiparticulate drug-delivery system based on pellets incorporated into congealable polyethylene glycol carrier materials **216**, 9
Schmook, F.P., J.G. Meingassner, A. Billich, Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption **215**, 51
Schöler, N., C. Olbrich, K. Tabatt, R.H. Müller, H. Hahn, O. Liesenfeld, Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages **221**, 57
Schröder, W., see Gessner, A. **214**, 87
Schubert, R., see Berger, N. **223**, 55
Schubert, R., see Pavelić, Ž. **219**, 139
Schubnell, M., J.E.K. Schawe, Quantitative determination of the specific heat and the glass transition of moist samples by temperature modulated differential scanning calorimetry **217**, 173
Schwartz, J.B., see DeCrosta, M.T. **213**, 45
Scolari, P., see Peira, E. **226**, 47
Scoppa, M., see Di Martino, P. **213**, 209
Şen, M., A. Yakar, Controlled release of antifungal drug terbinafine hydrochloride from poly(*N*-vinyl 2-pyrrolidone/itaconic acid) hydrogels **228**, 33
Senna, M., see Watanabe, T. **226**, 81
Seppälä, J., see Rich, J. **212**, 121
Sepulveda, P., see Netz, D.J.A. **213**, 117
Serra, M., see Franco, M. **225**, 63
Seshasayana, A., see Sreenivasa Rao, B. **230**, 1
Seta, Y., see Kamba, M. **228**, 209
Shah, N.H., see Mehta, K.A. **213**, 7
Shah, S.A., see Shishoo, C.J. **228**, 53
Shankar, R., see Singh, S. **228**, 5
Sheen, D.B., see Prasad, K.V.R. **215**, 29
Shefer, S., see Johnston, T.P. **229**, 75

Shen, Z., see Zhang, Q. **218**, 75
Sherwood, J.N., see Prasad, K.V.R. **215**, 29
Shibata, N., see Eaimtrakarn, S. **224**, 61
Shim, C.-K., see Kim, Y.G. **229**, 45
Shim, C.-K., see Lee, Y.-J. **224**, 201
Shimokawa, S., see Yokota, S. **223**, 69
Shin, S.-C., C.-W. Cho, I.-J. Oh, Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins **222**, 199
Shiozawa, K., see Fujii, M. **222**, 57
Shishoo, C.J., S.A. Shah, I.S. Rathod, S.S. Savale, M.J. Vora, Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation **228**, 53
Shitara, Y., see Kohda-Shimizu, R. **220**, 119
Shittu, A.O., see Orafidiya, L.O. **224**, 177
Shokri, J., A. Nokhodchi, A. Dashbolaghi, D. Hassan-Zadeh, T. Ghafourian, M. Barzegar Jalali, The effect of surfactants on the skin penetration of diazepam **228**, 99
Shu, X.Z., K.J. Zhu, W. Song, Novel pH-sensitive citrate cross-linked chitosan film for drug controlled release **212**, 19
Sigfússon, S.D., see Loftsson, T. **212**, 29
Sigurjónsdóttir, J.F., see Loftsson, T. **212**, 29
Sigurðsson, H.H., see Loftsson, T. **212**, 29
Simamora, P., J.M. Alvarez, S.H. Yalkowsky, Solubilization of rapamycin **213**, 25
Sims, E.E., see Brown, J.R. **213**, 127
Singh, B., see Singh, S. **228**, 5
Singh, J., see Rastogi, S.K. **225**, 75
Singh, J., see Rastogi, S.K. **215**, 241
Singh, J., see Zhao, K. **219**, 177
Singh, S., see Zhao, K. **219**, 177
Singh, S., T.T. Mariappan, R. Shankar, N. Sarda, B. Singh, A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem **228**, 5
Singla, A., see Lee, C.H. **221**, 1
Sinha, V.R., R. Kumria, Polysaccharides in colon-specific drug delivery **224**, 19
Sipahigil, O., B. Dortunç, Preparation and in vitro evaluation of verapamil HCl and ibuprofen containing carrageenan beads **228**, 119
Six, K., G. Verreck, J. Peeters, P. Augustijns, R. Kinget, G. Van den Mooter, Characterization of glassy itraconazole: a comparative study of its molecular mobility below $T_g$ with that of structural analogues using MTDSC **213**, 163
Škalko-Basnet, N., see Pavelić, Ž. **219**, 139
Sloan, K.B., see Beall, H.D. **217**, 127
Smart, J.D., see Riley, R.G. **217**, 87
Smeyers-Verbeke, J., see Adams, E. **226**, 107
Smeyers-Verbeke, J., see Adams, E. **212**, 41
Smith, G., see Reason, M. **222**, 121
Snowden, M.J., see Armstrong, J.K. **229**, 57
Snowden, M.J., see Michael, Y. **221**, 165
Soane, R.J., M. Hinchcliffe, S.S. Davis, L. Illum, Clearance characteristics of chitosan based formulations in the sheep nasal cavity **217**, 183
Sochor, J., see Klimeš, J. **217**, 153
Söderberg, I., see Bjerregaard, S. **215**, 13
Sokar, M.S., see El-Kamel, A.H. **220**, 13
Sommier, N., P. Porion, P. Evesque, B. Leclerc, P. Tchoreloff, G. Couarraze, Magnetic resonance imaging investigation of the mixing-segregation process in a pharmaceutical blender **222**, 243
Song, J.F., C.A. Lau-Cam, K.H. Kim, Monohydroxylation and esterification as determinants of the effects of *cis*- and *trans*-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro **212**, 153
Song, W., see Shu, X.Z. **212**, 19
Sonobe, T., see Nakamura, K. **222**, 91
Sonobe, T., see Yokota, S. **223**, 69
Sonohara, S., see Yokota, S. **223**, 69
Sournac, M., see Boucaud, A. **228**, 69
Spadaro, A.C.C., see Netz, D.J.A. **213**, 117
Špiclin, P., M. Gašperlin, V. Kmetec, Stability of ascorbyl palmitate in topical microemulsions **222**, 271
Spiller, R.C., see Perkins, A.C. **222**, 295
Srčič, S., see Planinšek, O. **221**, 211
Srčič, S., see Trojak, A. **218**, 145
Sreenivasa Rao, B., A. Seshasayana, S.V. Pardha Saradhi, N. Ravi Kumar, C.P.S. Narayan, K.V. Ramana Murthy, Correlation of 'in vitro' release and 'in vivo' absorption characteristics of rifampicin from ethylcellulose coated nonpareil beads **230**, 1
Stanilova, S., see Zheleva, A. **222**, 237
Stanley, P., Mechanical strength testing of compacted powders **227**, 27
Stefánsson, E., see Loftsson, T. **212**, 29
Stenekes, R.J.H., A.E. Loebis, C.M. Fernandes, D.J.A. Crommelin, W.E. Hennink, Degradable dextran microspheres for the controlled release of liposomes **214**, 17
Stengele, A., S. Rey, H. Leuenberger, A novel approach to the characterization of polar liquids: Part 1: pure liquids **225**, 123
Stepensky, D., see Hoffman, A. **220**, 1
Storm, G., see Oussoren, C. **214**, 1
Storm, G., see Schiffelers, R.M. **214**, 103
Storm, G., see Verbaan, F.J. **214**, 99
Stott, P.W., A.C. Williams, B.W. Barry, Mechanistic study into the enhanced transdermal permeation of a model β-blocker, propranolol, by fatty acids: a melting point depression effect **219**, 161
Stout, P.J., see Prabhu, S. **217**, 71
Sugano, K., H. Hamada, M. Machida, H. Ushio, K. Saitoh, K. Terada, Optimized conditions of bio-mimetic artificial membrane permeation assay **228**, 181
Sugawara, M., see Kobayashi, M. **221**, 87
Sugibayashi, K., M. Yoshida, K. Mori, T. Watanabe, T. Hasegawa, Electric field analysis on the improved skin concentration of benzoate by electroporation **219**, 107
Sugibayashi, K., see Miyamoto, M. **226**, 127

Suihko, E., O. Korhonen, T. Järvinen, J. Ketolainen, P. Jarho, E. Laine, P. Paronen, Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-β-cyclodextrin **215**, 137
Suihko, E., V.-P. Lehto, J. Ketolainen, E. Laine, P. Paronen, Dynamic solid-state and tableting properties of four theophylline forms **217**, 225
Sun, C., D.J.W. Grant, Effects of initial particle size on the tableting properties of L-lysine monohydrochloride dihydrate powder **215**, 221
Sundelöf, L.-O., see Brounéus, F. **218**, 57
Sung, K.C., see Yen, S.-Y. **220**, 91
Sun, R., see Wu, H. **221**, 23
Suzuki, S., see Miyazaki, S. **229**, 29
Suzuki, T., see Morita, T. **219**, 127
Svendsen, O., see Larsen, S.W. **230**, 67
Szachowicz-Petelska, B., Z. Figaszewski, W. Lewandowski, Mechanisms of transport across cell membranes of complexes contained in antitumour drugs **222**, 169
Sznitowska, M., see Cal, K. **224**, 81
Szwarocka, A., A. Kowalczyk, D. Łubgan, Z. Jóźwiak, The combined effect of IDA and glutaraldehyde on the properties of human erythrocytes **220**, 43

Tabatt, K., see Schöler, N. **221**, 57
Tabibi, S.E., see Jain, N. **225**, 41
Tabibi, S.E., see Ni, N. **226**, 39
Tabrizian, M., see Moisan, M. **226**, 1
Tajarobi, F., M. El-Sayed, B.D. Rege, J.E. Polli, H. Ghandehari, Transport of poly amidoamine dendrimers across Madin–Darby canine kidney cells **215**, 263
Takada, K., see Eaimtrakarn, S. **224**, 61
Takahashi, A., see Miyazaki, S. **229**, 29
Takahashi, K., see Yokota, S. **223**, 69
Takakura, Y., see Verbaan, F.J. **214**, 99
Takayama, K., see Junping, W. **219**, 183
Takayama, K., see Morishita, M. **212**, 289
Takayama, K., see Obata, Y. **212**, 223
Takeda, Y., see Yokogawa, K. **229**, 183
Tamai, I., see Ishikawa, F. **224**, 105
Tanaka, T., see Nakamura, K. **222**, 91
Taneja, R., see Gharat, L. **219**, 1
Tardi, C., M. Drechsler, K.H. Bauer, M. Brandl, Steam sterilisation of vesicular phospholipid gels **217**, 161
Taylor, K.M.G., see Batavia, R. **212**, 109
Taylor, K.M.G., see Castile, J.D. **221**, 197
Taylor, K.M.G., see Khatri, L. **227**, 121
Taylor, L.S., see Broman, E. **222**, 139
Tchoreloff, P., see Sommier, N. **222**, 243
Teesdale-Spittle, P., see Reason, M. **222**, 121
Teixeira, M.F.S., O. Fatibello-Filho, Flow injection potentiometric determination of bismuth(III) in anti-acid formulations **221**, 115
Terada, K., see Sugano, K. **228**, 181
Tesconi, M., see Ni, N. **226**, 39
Thielmann, F., see Newell, H.E. **217**, 45
Thomas, M., see Batavia, R. **212**, 109
Thomas, N.S., see Panchagnula, R. **219**, 95
Thomsen, A.E., see Larsen, S.W. **216**, 83
Thünemann, A.F., see General, S. **230**, 11
Titeva, S., see Michailova, V. **222**, 7
Tiwary, A.K., see Dureja, H. **213**, 193
Tønnesen, H.H., Formulation and stability testing of photolabile drugs **225**, 1
Tobiska, S., P. Kleinebudde, A simple method for evaluating the mixing efficiency of a new type of pan coater **224**, 141
Todo, H., H. Okamoto, K. Iida, K. Danjo, Effect of additives on insulin absorption from intratracheally administered dry powders in rats **220**, 101
Tokiwa, S., see Morishita, M. **212**, 289
Tokumura, T., Y. Machida, UV absorption method should not be applied for determining amoxycillin in acidic dissolution test medium **228**, 1
Tomer, G., F. Podczeck, J.M. Newton, The influence of type and quantity of model drug on the extrusion/spheronization of mixtures with microcrystalline cellulose: I. Extrusion parameters **217**, 237
Tomlinson, B., see Yin, O.Q.P. **222**, 305
Török, G., see Farkas, E. **213**, 1
Torrado, G., C. Carrascosa, S. Torrado-Santiago, Correlation of in vitro and in vivo acetaminophen availability from albumin microaggregates oral modified release formulations **217**, 193
Torrado-Santiago, S., see Torrado, G. **217**, 193
Torrado, S., P. Frutos, G. Frutos, Gentamicin bone cements: characterisation and release (in vitro and in vivo assays) **217**, 57
Toscani, S., see Zerrouk, N. **225**, 49
Trapani, G., see Franco, M. **225**, 63
Trapani, G., see Puglia, C. **228**, 79
Trividic, A., see Raghavan, S.L. **212**, 213
Trojak, A., K. Kočevar, I. Muševič, S. Srčič, Investigation of the felodipine glassy state by atomic force microscopy **218**, 145
Trojak, A., see Planinšek, O. **221**, 211
Tromelin, A., G. Hautbout, Y. Pourcelot, Application of fractal geometry to dissolution kinetic study of a sweetener excipient **224**, 131
Tsai, T.-H., C.-C. Liang, Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis **216**, 61
Tsai, Y.-H., see Fang, J.-Y. **215**, 91
Tsai, Y.-H., see Wu, P.-C. **222**, 225
Tsibouklis, J., see Riley, R.G. **217**, 87
Tsuda, Y., see Kohda-Shimizu, R. **220**, 119
Tsuji, A., see Ishikawa, F. **224**, 105
Tsybovsky, I.S., see Kisel, M.A. **216**, 105
Tucker, I.G., see Walker, G.F. **216**, 77
Tucker, I., see Forster, A. **226**, 147
Tullio, C., see Franco, M. **225**, 63
Tunón, Å., G. Alderborn, Granule deformation and densification during compression of binary mixtures of granules **222**, 65

Uchegbu, I.F., *Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs*, Edited by R.H. Muller, S. Benita, B. Bohm, Medpharm Scientific Publishers, Stuttgart, 1998. ISBN 3-88763-069-6 **212**, 143
Uchegbu, I.F., L. Sadiq, M. Arastoo, A.I. Gray, W. Wang, R.D. Waigh, A.G. Schätzleinä, Quaternary ammonium palmitoyl glycol chitosan—a new polysoap for drug delivery **224**, 185
Uchegbu, I.F., see Brown, M.D. **229**, 1
Uchida, T., see Yokota, S. **223**, 69
Uekama, K., see Nagase, Y. **229**, 163
Ungphaiboon, S., Y. Maitani, In vitro permeation studies of triamcinolone acetonide mouthwashes **220**, 111
Upadhyay, P., Electroporation of the skin to deliver antigen by using a piezo ceramic gas igniter **217**, 249
Ushio, H., see Sugano, K. **228**, 181
Usui, F., see Watanabe, T. **226**, 81

Vaddi, H.K., L.Z. Wang, P.C. Ho, S.Y. Chan, Effect of some enhancers on the permeation of haloperidol through rat skin in vitro **212**, 247
Vaillant, L., see Boucaud, A. **228**, 69
Valcarenghi, D., see Bürger, C. **223**, 29
Vale, F.M., see Bettencourt, A. **219**, 89
Valenta, C., M. Nowak, J. Hadgraft, Influence of phloretin and 6-ketocholestanol on the permeation of progesterone through porcine skin **217**, 79
van Dam, I.M., see Verbaan, F.J. **214**, 99
Vandelli, M.A., F. Rivasi, P. Guerra, F. Forni, R. Arletti, Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies **215**, 175
Vandelli, M.A., see Pignatello, R. **218**, 27
van den Bergh, B.A.I., P.W. Wertz, H.E. Junginger, J.A. Bouwstra, Elasticity of vesicles assessed by electron spin resonance, electron microscopy and extrusion measurements **217**, 13
Van den Mooter, G., see Maris, B. **213**, 143
Van den Mooter, G., see Six, K. **213**, 163
Van den Mooter, G., see Verheyen, S. **228**, 199
Vander Heyden, Y., see Adams, E. **212**, 41
VanDer Kamp, D., see Luner, P.E. **212**, 81
Van Driessche, I., see Vergote, G.J. **219**, 81
van Emst, J.L., see van Oosterhout, Y.V.J.M. **221**, 175
Van Gelder, J.M., see Hoffman, A. **220**, 1
van Oosterhout, Y.V.J.M., J.L. van Emst, H.H. Bakker, F.W.M.B. Preijers, A.V.M.B. Schattenberg, D.J. Ruiter, S. Evers, J.P. Koopman, T. de Witte, Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study **221**, 175
Van Reeth, K., see Maris, B. **213**, 143
Van Winkle, L.L., see Viegas, T.X. **219**, 73
Vaugelade, C., A.-C. Rohmer, F. Burel, J. Belleney, R. Duclos, C. Bunel, Progesterone freeze-dried systems in sublingual dosage form **229**, 67
Vázquez, J.L., S. Merino, Ò. Domènech, M. Berlanga, M. Viñas, M.T. Montero, J. Hernández-Borrell, Determination of the partition coefficients of a homologous series of ciprofloxacin: influence of the *N*-4 piperazinyl alkylation on the antimicrobial activity **220**, 53
Vedstesen, H., see Bjerregaard, S. **215**, 13
Velnar, M., see Burjak, M. **224**, 123
Vepsäläinen, J., see Raiman, J. **213**, 135
Verbaan, F.J., C. Oussoren, I.M. van Dam, Y. Takakura, M. Hashida, D.J.A. Crommelin, W.E. Hennink, G. Storm, The fate of poly(2-dimethyl amino ethyl)methacrylate-based polyplexes after intravenous administration **214**, 99
Vergote, G.J., C. Vervaet, I. Van Driessche, S. Hoste, S. De Smedt, J. Demeester, R.A. Jain, S. Ruddy, J.P. Remon, An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen **219**, 81
Verheyden, L., see Maris, B. **213**, 143
Verheyen, S., P. Augustijns, R. Kinget, G. Van den Mooter, Determination of partial solubility parameters of five benzodiazepines in individual solvents **228**, 199
Vermehren, C., K. Jørgensen, R. Schiffelers, S. Frokjaer, Activity of mammalian secreted phospholipase $A_2$ from inflammatory peritoneal fluid towards PEG-liposomes. Early indications **214**, 93
Vermehren, C., see Bjerregaard, S. **215**, 13
Vermehren, C., see Davidsen, J. **214**, 67
Verreck, G., see Six, K. **213**, 163
Vervaet, C., see De Kerf, M. **221**, 69
Vervaet, C., see Vergote, G.J. **219**, 81
Veski, P., see Nykänen, P. **229**, 155
Viegas, T.X., L.L. Van Winkle, P.A. Lehman, S.F. Franz, T.J. Franz, Evaluation of creams and ointments as suitable formulations for peldesine **219**, 73
Vignardet, C., Y.C. Guillaume, L. Michel, J. Friedrich, J. Millet, Comparison of two hard keratinous substrates submitted to the action of a keratinase using an experimental design **224**, 115
Vigneron, C., see Zambaux, M.F. **212**, 1
Villafuerte, L., see Juárez, H. **216**, 115
Villafuerte-Robles, L., see López-Solís, J. **216**, 127
Viñas, M., see Vázquez, J.L. **220**, 53
Vincent, R.M., see Perkins, A.C. **222**, 295
Vincieri, F.F., see Bilia, A.R. **213**, 199
Vincieri, F.F., see Mulinacci, N. **216**, 23
Viseras, C., P. Cerezo, G.H. Meeten, A. Lopez-Galindo, One-dimensional filtration of pharmaceutical grade phyllosilicate dispersions **217**, 201
Vistelle, R., see Hoizey, G. **229**, 147
Vlahakis, T.L., see Gebauer, M.G. **223**, 49
Vlasov, A.P., see Kisel, M.A. **216**, 105
Voinovich, D., see Moneghini, M. **222**, 129
Vora, M.J., see Shishoo, C.J. **228**, 53
Vorob'yov, M.S., see Kisel, M.A. **216**, 105
Vyas, S.P., see Agarwal, R. **228**, 43

Waaler, P.J., see Gleditsch, E. **212**, 275
Wada, K., see Nagase, Y. **229**, 163
Waigh, R.D., see Uchegbu, I.F. **230**, 77
Waigh, R.D., see Uchegbu, I.F. **224**, 185

Wakiyama, N., see Watanabe, T. **226**, 81
Waksman, N., see Caballero-Quintero, A. **229**, 23
Walker, G.F., R. Ledger, I.G. Tucker, Activity of pancreatic endopeptidases towards luteinizing hormone-releasing hormones **216**, 77
Wang, J.-J., see Yen, S.-Y. **220**, 91
Wang, J., see Pan, X. **220**, 33
Wang, L.Z., see Vaddi, H.K. **212**, 247
Wang, W., see Uchegbu, I.F. **230**, 77
Wang, W., see Uchegbu, I.F. **224**, 185
Wang, Y., see Nazzal, S. **230**, 35
Wang, Y.-Y., C.-T. Hong, W.-T. Chiu, J.-Y. Fang, In vitro and in vivo evaluations of topically applied capsaicin and nonivamide from hydrogels **224**, 89
Wang, Y.-Y., see Fang, J.-Y. **219**, 61
Washington, C., see Han, J. **215**, 207
Watanabe, T., N. Wakiyama, F. Usui, M. Ikeda, T. Isobe, M. Senna, Stability of amorphous indomethacin compounded with silica **226**, 81
Watanabe, T., see Sugibayashi, K. **219**, 107
Watanabe, Y., see Fujii, M. **222**, 57
Weerapreeyakul, N., see Gharat, L. **219**, 1
Weiner, N.D., see Wu, H. **221**, 23
Weiner, N.D., see Wu, H. **220**, 63
Weisman, A., I. Kuselman, Distributions of results of cetirizine dihydrochloride assay in bulk material **221**, 159
Wenderoth, D., see Perkins, A.C. **222**, 295
Wertz, P.W., see van den Bergh, B.A.I. **217**, 13
Wickens, H.J., R.J. Pinney, Investigation of Smith's quinolone killing mechanisms during the PAE of ciprofloxacin on *Escherichia coli* **227**, 149
Wiese, M., see Peinhardt, G. **215**, 83
Wigent, R.J., see DeCrosta, M.T. **213**, 45
Wilber, W.R., see Riley, R.G. **217**, 87
Williams, A.C., see Mackay, K.M.B. **228**, 89
Williams, A.C., see Stott, P.W. **219**, 161
Williams, D.R., see Newell, H.E. **217**, 45
Willson, R.J., see Zaman, F. **227**, 133
Wilson, C.G., see Perkins, A.C. **222**, 295
Wirth, M., see Gabor, F. **221**, 35
Wong, J.W., K.H. Yuen, Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins **227**, 177
Wu, H., C. Ramachandran, A.U. Bielinska, K. Kingzett, R. Sun, N.D. Weiner, B.J. Roessler, Topical transfection using plasmid DNA in a water-in-oil nanoemulsion **221**, 23
Wu, H., C. Ramachandran, N.D. Weiner, B.J. Roessler, Topical transport of hydrophilic compounds using water-in-oil nanoemulsions **220**, 63
Wu, P.-C., J.-S. Chang, Y.-B. Huang, C.-Y. Chai, Y.-H. Tsai, Evaluation of percutaneous absorption and skin irritation of ketoprofen through rat skin: in vitro and in vivo study **222**, 225
Wu, P.-C., see Fang, J.-Y. **215**, 91

Yahia, L.H., see Moisan, M. **226**, 1
Yakar, A., see Şen, M. **228**, 33
Yalkowsky, S.H., see Jain, N. **225**, 41
Yalkowsky, S.H., see Ni, N. **226**, 39
Yalkowsky, S.H., see Simamora, P. **213**, 25
Yalkowsky, S.H., see Zhao, L. **218**, 43
Yamada, H., see Kohda-Shimizu, R. **220**, 119
Yamaguchi, M., see Miyamoto, M. **226**, 127
Yamamoto, K., see Nakamura, K. **218**, 93
Yamamura, S., Y. Momose, Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data **212**, 203
Yanai, S., T. Sakthivel, A.T. Florence, Interfacial behaviour and micelle formation of novel amphiphilic sequential lipid–lysine oligomers **214**, 49
Yang, G., see Jain, N. **225**, 41
Yasukawa, K., see Ishida, T. **224**, 69
Yasuura, H., see Nakamichi, K. **218**, 103
Yazaki, E., see Chaw, C.S. **227**, 167
Yazdanian, M.A., see Hamilton, K.O. **228**, 171
Yen, S.-Y., K.C. Sung, J.-J. Wang, O. Yoa-Pu Hu, Controlled release of nalbuphine propionate from biodegradable microspheres: in vitro and in vivo studies **220**, 91
Ygartua, P., see de Jalón, E.G. **226**, 181
Ygartua, P., see Doliwa, A. **229**, 37
Yin, O.Q.P., B. Tomlinson, A.H.L. Chow, M.S.S. Chow, Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects **222**, 305
Yliruusi, J., see Korhonen, M. **221**, 187
Yliruusi, J., see Luukkonen, P. **216**, 147
Yli-Urpo, A., see Kortesuo, P. **221**, 107
Yli-Urpo, A., see Rich, J. **212**, 121
Yoa-Pu Hu, O., see Yen, S.-Y. **220**, 91
Yokogawa, K., T. Nakaharu, J. Ishizaki, E. Ozaki, Y. Takeda, H. Mabuchi, R. Matsushita, K. Kimura, E. Nakashima, F. Ichimura, K.-i. Miyamoto, Kinetic phenotypic diagnosis of *N*-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine **229**, 183
Yokohama, S., see Nakamura, K. **222**, 91
Yokohama, S., see Yokota, S. **223**, 69
Yokota, S., S. Sonohara, M. Yoshida, M. Murai, S. Shimokawa, R. Fujimoto, S. Fukushima, S. Kokubo, K. Nozaki, K. Takahashi, T. Uchida, S. Yokohama, T. Sonobe, A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration **223**, 69
Yoncheva, K., S. Miloshev, N. Belcheva, N. Lambov, Development and characterization of cross-linked poly(malate) microspheres with dipyridamole **226**, 31
Yoneyama, T., see Fukui, E. **217**, 33
Yoneyama, T., see Murakami, H. **216**, 159
Yong, C.S., J.S. Choi, Q.-Z. Quan, J.-D. Rhee, C.-K. Kim, S.-J. Lim, K.-M. Kim, P.-S. Oh, H.-G. Choi, Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium **226**, 195
Yong, C.-S., see Kim, K.-E. **217**, 101
York, P., see Jouyban-Gharamaleki, A. **216**, 33
Yoshida, M., see Sugibayashi, K. **219**, 107
Yoshida, M., see Yokota, S. **223**, 69

Yoshikawa, Y., see Eaimtrakarn, S. **224**, 61
Yoshino, H., see Morita, T. **219**, 127
Yritys, K., see Raiman, J. **213**, 135
Yuasa, H., see Nakano, T. **215**, 3
Yuen, K.H., see Wong, J.W. **227**, 177
Yu, S.-Y., see Fang, J.-Y. **215**, 91

Zabarovskaya, Z.V., see Kisel, M.A. **216**, 105
Zaman, F., A.E. Beezer, J.C. Mitchell, Q. Clarkson, J. Elliot, A.F. Davis, R.J. Willson, The stability of benzoyl peroxide by isothermal microcalorimetry **227**, 133
Zaman, F., A.E. Beezer, J.C. Mitchell, Q. Clarkson, J. Elliot, M. Nisbet, A.F. Davis, The stability of benzoyl peroxide formulations determined from isothermal microcalorimetric studies **225**, 135
Zambaux, M.F., F. Bonneaux, R. Gref, E. Dellacherie, C. Vigneron, Protein C-loaded monomethoxypoly (ethylene oxide)–poly(lactic acid) nanoparticles **212**, 1
Zambito, Y., see Di Colo, G. **220**, 169
Zambito, Y., see Di Colo, G. **215**, 101
Zelkó, R., see Farkas, E. **213**, 1
Zeng, X.M., G.P. Martin, C. Marriott, Effects of molecular weight of polyvinylpyrrolidone on the glass transition and crystallization of co-lyophilized sucrose **218**, 63
Zerrouk, N., C. Chemtob, P. Arnaud, S. Toscani, J. Dugue, In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions **225**, 49
Zhang, Q., Z. Shen, T. Nagai, Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats **218**, 75
Zhang, X., R. Mehvar, Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats **229**, 173
Zhao, H., see Kim, M.-K. **219**, 51
Zhao, K., S. Singh, J. Singh, Effect of menthone on the in vitro percutaneous absorption of tamoxifen and skin reversibility **219**, 177
Zhao, L., S.H. Yalkowsky, Stabilization of eptifibatide by cosolvents **218**, 43
Zheleva, A.M., V.G. Gadjeva, Spin labelled nitrosoureas and triazenes and their non-labelled clinically used analogues — a comparative study on their physicochemical properties and antimelanomic effects **212**, 257
Zheleva, A., S. Stanilova, Z. Dobreva, Z. Zhelev, Two glycine containing 2-chloroethylnitrosoureas—a comparative study on some physicochemical properties, in vivo antimelanomic effects and immunomodulatory properties **222**, 237
Zhelev, Z., see Zheleva, A. **222**, 237
Zhu, H., D.J.W. Grant, Dehydration behavior of nedocromil magnesium pentahydrate **215**, 251
Zhu, K.J., see Qiu, L.Y. **219**, 151
Zhu, K.J., see Shu, X.Z. **212**, 19
Zhu, L., V. Kumar, G.S. Banker, Examination of oxidized cellulose as a macromolecular prodrug carrier: preparation and characterization of an oxidized cellulose-phenylpropanolamine conjugate **223**, 35
Zoestbergen, E., see Bolhuis, G.K. **221**, 77
Zorc, B., see Zovko, M. **228**, 129
Zovko, M., B. Zorc, M. Lovrek, B. Boneschans, Macromolecular prodrugs. IX. Synthesis of polymer-fenoprofen conjugates **228**, 129
Zuleger, S., B.C. Lippold, Polymer particle erosion controlling drug release. I. Factors influencing drug release and characterization of the release mechanism **217**, 139

ELSEVIER

International Journal of Pharmaceutics 230 (2001) 105–121

international journal of pharmaceutics

www.elsevier.com/locate/ijpharm

# Subject Index Volumes 212–230 (2001)

Absorption (220), 119
Absorption enhancer (226), 127
Absorption enhancers (217), 111; (222), 109
Absorption in vivo (230), 1
Absorptive endocytosis (225), 97
Accelerated studies (212), 275
Acetaminophen (217), 193; (222), 305
Acetazolamide (213), 209
p-Acetoxy acetamilide (215), 29
Acetylcholinesterase (AChE) inhibitor (212), 267
Acetylsalicylic acid (216), 95; (227), 39
Acidic drug (226), 69
Acidic solution (228), 1
Acoustic emission (220), 85
Active transport (221), 35
Acylated peptide (214), 77
Adhesion (227), 47, 113
Adsorption (214), 71; (224), 201; (229), 163
Adsorption isotherm (218), 153
Agarose (218), 57
Agglomeration (215), 3
Agglomeration state (227), 97
Aggregation (221), 165
Albumin (214), 99; (229), 23
Albumin microaggregates (217), 193
Aldehyde (215), 45
Alginate gels (220), 161
3-Alkylcarbonyl-5-fluorouracil (217), 127
Alloxan diabetes (216), 105
All-trans retinoic acid (221), 123
All-*trans*-retinoic acid (215), 67
Aluminum ion (222), 91
2-Amino-2-methyl-1,3-propanediol (226), 163
2-Amino-2-methylpropanol (226), 163
4-Aminopyridine (216), 115
5-aminosalicylic acid (213), 93
Amorphous (216), 43; (217), 45; (222), 139
Amorphous drugs (213), 163
Amorphous raffinose (227), 57
Amoxycillin (228), 1
Amphiphatic peptides (228), 109
Amphiphilic polymer (226), 23
Amphotericin B (213), 153
Antacids (226), 61
Anthocyanins (216), 23
Anti-acid formulations (221), 115
Antibacterial activity (224), 177
Antibacterials (227), 149
Antibodies (224), 69
Antibody (215), 45
Antibody response (217), 215
Anticancer drug delivery system (219), 1
Anti-clastic plate bending (227), 39
Anticonvulsant activity (225), 63
Antigen delivery (217), 249
Antigen delivery system (221), 153
Antigens CD3 & CD7 (221), 175
Antihypertensive effect (215), 175
Anti-inflammatory effect (222), 45
Antimycotics (219), 11
Antinucleant polymers (221), 95
Antiplatelet agent (226), 31
Antisense (214), 13
Antisense therapy (214), 25
Antisolvent (228), 19
Antitumor (217), 101
Antitumor effect (226), 93
Antitumour drugs (222), 169
Antoine equation (213), 31
Apomorphine (226), 47
Apoprotein B (228), 109

PII: S0378-5173(01)00889-4

Artemisinin (227), 177
Artificial neural networks (226), 207
Artificial neural networks (ANN) (212), 223
Ascorbyl palmitate (222), 271
Asparaginase (217), 215
Asparagus pea lectin (215), 153
Assay (221), 159
Atherosclerosis (229), 75
Atomic force microscopy (218), 145
ATR-FTIR spectroscopy (216), 51; (219), 161
ATR-IR spectroscopy (221), 95
Attachment (215), 45
Attenuated total reflectance Fourier transform infrared (see ATR-FTIR spectroscopy)
Autoclaving (217), 161
Avidin (214), 63
Azone (222), 225
Azo polymers (213), 143

Bacteria (227), 157
Bacterial susceptiblity (214), 103
Bases in formulation (224), 177
Batch quality (221), 159
BCX-34 (219), 73
Beads (228), 119
Beclomethasone dipropionate (212), 109; (215), 113
Benzalkonium chloride (229), 131
Benzodiazepines (212), 29; (228), 199
Benzoic acid (216), 51; (228), 189
Benzophenone 4 (222), 153
Benzoyl peroxide (225), 135; (227), 133
Benzylamine (226), 163
Bile acids (229), 75
Bile extract (222), 217
Bile salt-lipid solutions (212), 81
Bile salts (217), 111
Binding (229), 23
Bioadhesion (214), 83; (217), 87, 183; (221), 35
Bioavailability (212), 233; (217), 121; (218), 93, 125; (219), 81; (220), 1; (222), 1; (224), 105; (225), 49; (227), 177; (228), 53; (229), 193
Bioavailability problem (228), 5
Bioavailability study (221), 227
Biocompatibility (215), 175
Biodegradable microspheres (215), 67; (219), 127; (221), 153; (226), 31
Biodegradable nanoparticles (212), 1
Biodegradable nanospheres (214), 31
Biodegradable polymer (223), 69; (229), 107
Biodegradable polymers (212), 11, 121; (230), 57
Biodegradation (222), 183
Biodisposition (226), 93
Biodistribution (215), 197; (221), 143
Biomaterial (219), 89; (221), 1
Biotin (214), 63
Biphasic release (226), 139
Bismuth(III) tubular ion-selective electrode (221), 115
Bisphosphonate (220), 1
Bisphosphonates (213), 135
Blood–brain barrier (216), 61
B16 melanoma (222), 237
Bone cement (219), 89
Bone morphogenetic protein (223), 69
Bovine serum albumin (222), 77
Brain delivery (212), 267
Brij-30 (229), 213
BTA-243 (213), 127
Buccal absorption (212), 289
Buccal tablet (220), 129
Buformin tosylate (218), 13
Bulk crystallization (215), 29
Buoyancy (218), 103
Bupravaquone (214), 3, 83
Buprenorphine (217), 121
Burst effect (216), 165

Caco-2 (219), 1; (221), 87; (222), 77
Caco-2 cells (213), 127, 135; (224), 201
Caffeine (228), 69; (229), 131
Calcium carbonate (224), 105
Calcium lactate (221), 77
Calcium stearate (216), 137
Calorimetry (213), 45; (225), 135; (227), 133
Calu-3 (228), 171
Capillary rheometer (216), 147
Capsaicin (224), 89
Carbamazepine (222), 129; (225), 49
Carbodiimide (223), 35
Carbopol (214), 3
Carbopol 934P (212), 55
6-Carboxycellulose (223), 35

Carboxymethylcellulose (213), 75; (216), 115; (224), 113
Carboxymethylcellulose–cysteamine conjugate (226), 185
Carrageenan (228), 119
Cationic liposomes (229), 1
Cationized human serum albumin (225), 97
C3bgp (222), 237
Cell culture (218), 81
Cell membranes (222), 169
Cellulose nitrate membrane microcapsules (215), 185
Central composite design (213), 193; (220), 149
Centella asiatica (220), 141
Cephalosporin antibiotics (220), 119
Cerebrospinal fluid (CSF) (212), 267
Certirizine dihydrochloride (221), 159
CFC-113 (221), 165
Characterisation (213), 13
Chemical enhancers (229), 131
Chemometrics (212), 41
Chicken ovomucoid (225), 31
Chiral enantiomers (228), 89
Chitosan (214), 3, 83; (217), 183; (224), 123, 159, 185; (226), 139
Chitosan film (212), 19
Chitosan membrane (213), 193
1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea (226), 39
Chlorofluorocarbon (222), 101
Chloroquine (218), 81
Cholestyramine (212), 55
Cholic acid (226), 23
α-Chymotrypsin (217), 111
CIELAB units (213), 63
Cimetidine (220), 161
Ciprofloxacin (227), 149
Cis- and trans- 9-octadecenoic acids (212), 153
Citric acid (220), 101; (229), 155
Clausius–Mossotti equation (225), 123
Clinical isolates (224), 177
Clinical pharmacokinetics (213), 153
Clodronate (213), 135
Clonazepam (228), 79
Clonidine hydrochloride physical properties (215), 175
Clorhexidine base and salts (213), 1
Clotrimazole (215), 51
Cloud point (226), 53
Coacervation (215), 185
Coating (213), 63; (216), 9, 67
Coenzyme $Q_{10}$ (212), 233
Coevaporates (218), 27
Co-extrusion (227), 71
Co-ground mixture (226), 81
Collagen (221), 1
Collapse (217), 45
Colon (227), 157
Colonic delivery (213), 83, 93
Colon-specific drug delivery (224), 19; (229), 155
Colon targeting (213), 143; (224), 19
Colorimetry (222), 225
Colour uniformity (213), 63
Commercial extract and capsules (213), 199
Compactibility (216), 159
Compaction (213), 45
Compaction calorimeter (213), 45
Complement activation (224), 69
Complement system (215), 197
Complex (222), 91
Complexation (212), 29; (217), 71
Compressibility (216), 159
Compression behaviour (213), 209
Compression tooling (215), 123
Confocal laser scanning microscopy (225), 97; (229), 117
Congealing (216), 9
Conjugates (215), 153
Contact angle (212), 81; (221), 211
Contact surface materials (227), 47
Container (224), 51
Container permeation (221), 49
Contraction (219), 113
Controlled-drug delivery (222), 259
Controlled drug delivery (215), 101; (217), 139; (220), 169
Controlled release (214), 17; (220), 91; (222), 183; (224), 151; (228), 119
Controlled-release (213), 83, 93
Controlled release (213), 7
Coprecipitates (225), 31
Cornish-Bowden plot (212), 171
Cosolvency (216), 33
Cosolvent (213), 25
Cosolvents (212), 213; (218), 43; (221), 95
Co-spray drying (216), 43
Creatine kinase (212), 11
Creatinine (229), 205

Critical stress intensity factor (227), 39
Cross-linked chitosan iron (III) (223), 29
Cross-linked gelatin (213), 103
Crosslinking (226), 185
Cryptosporidium (214), 3, 83
Crystal (212), 109
Crystal habit (215), 29
Crystalline (222), 139
Crystallisation (212), 131, 213; (216), 43; (218), 63, 145; (226), 81
CWJ-a-5 (217), 101
β-Cyclodextrin (222), 45
Cyclodextrin (212), 29; (225), 15
γ-cyclodextrins (227), 177
β-cyclodextrins (227), 177
Cyclodextrins (217), 111
Cyclosporin A (216), 17; (218), 125; (224), 159, 201
Cynomolgus monkey (221), 175
Cysteine (229), 45
Cytokines (221), 57
Cytotoxicity (221), 57

Damping (228), 139
Danazol (212), 177
Debye equation (225), 123
Decompression (213), 45
Decompression heat (213), 45
Decompression work (213), 45
Defect/strain content (215), 29
Deformation (222), 65
Degradable (214), 17
Degradation (214), 67, 93; (222), 205
DEHP (229), 139
Dehydration (215), 251; (220), 33
Dehydroepiandrosterone (214), 43
Dendrimers (214), 71; (229), 1
Densification (219), 113; (222), 65; (227), 81
Densification behaviour (213), 209
Density (218), 153
Dermal anesthesia (222), 35
Dermal delivery (225), 113
Dermal formulations (219), 73
25-Desacetylrifampicin (228), 53
Desorption (223), 1
Desorptivity (217), 201
Destructive force (228), 209
Determination method (228), 1
Dexamethasone (229), 205
Dexmedetomidine (221), 107
Dextran-methylprednisolone conjugate (229), 173
Dextran microspheres (214), 17
Dextrin (218), 125
Dextrins (230), 57
Diazepam (228), 99
Dibutyl sebacate (217), 33
Diclofenac (225), 113; (226), 163
Diclofenac salts (222), 281
Diclofenac sodium (216), 67; (217), 153; (226), 195
Dielectric dispersion (227), 139
Dielectric permittivity (225), 123
Diethylamine (222), 281
Differential scanning calorimetry (212), 177; (216), 43; (219), 39; (221), 197; (227), 57; (229), 57
Diffusion (217), 71, 79
Diffusional barrier (215), 185
Diffusion cell experiments (217), 127
Diffusion coefficient (218), 57
Diffusion mechanism (212), 213
Diflunisal (218), 27
Diltiazem hydrochloride (220), 77
Dimethyl aniline (225), 41
Diprivan® (215), 207
Direct compaction (221), 77
Direct compression (226), 61
Disappearance rates (215), 13
Disapperance rates (230), 67
Disintegrant (226), 61
Disintegrants (216), 127
Disintegration (221), 69
Diskus® inhaler (228), 219
Disperse systems (217), 201
Dissolution (212), 41, 81, 177; (216), 127, 137; (217), 71; (218), 103; (220), 77; (222), 281; (224), 39; (225), 49; (226), 107
Dissolution kinetic (224), 131
Dissolution properties (225), 63
Dissolution rate (213), 127
Dissolution stability (225), 31
Dissolution test (228), 1
Distribution (214), 99; (221), 159
Distribution coefficients (213), 127
Dithranol (228), 43
Dixon plot (212), 171

DMP 754 (223), 81
DMSO (228), 181
Dog (228), 209
DOPA-oxidase activity (212), 257
Double emulsion (214), 25
Doxorubicin (213), 103
DPPC (217), 25
Drug controlled release (212), 19
Drug delivery (214), 93; (215), 263; (216), 165; (221), 107; (224), 159; (225), 15; (227), 157; (229), 57
Drug delivery (214), 67, 83
Drug delivery system (224), 69; (226), 31
Drug/excipient interactions (226), 147
Drug formulations (224), 51
Drug-liquid crystalline system interactions (212), 73
Drug–polymer conjugates (230), 57
Drug–polymer interactions (225), 83
Drug/protein/gene delivery (221), 1
Drug release (212), 121; (215), 175; (218), 13; (220), 77
Drug release models (220), 77
Drugs (221), 219
Drug targeting (214), 63, 87, 103; (228), 109
Dry emulsion (212), 187, 195
Dry eye (224), 159
Dry granulation process (220), 129
Drying (219), 113; (227), 97
Drying rate (227), 81
Dry powder (220), 101
Dry powder inhalation (223), 15
DSC (217), 79
Du-145 (221), 35
Duck ovomucoid (225), 31
Duck parvovirus (221), 153
DY-9760e (229), 163
Dynamic mechanical spectrometer (228), 139
Dynamic rheological tests (221), 187

Effect of dose (221), 143
Effect of plasticizer (213), 7
Ejection (213), 45
Ejection heat (213), 45
Ejection work (213), 45
Elasticity (217), 13; (228), 139
Elastic parameters (216), 147
Elcatonin (224), 105
Electrical impedance tomography (EIT) (227), 167
Electric field analysis (219), 107
Electron beam (221), 69
Electronbeam-irradiation (222), 205
Electron microscopy (217), 13
Electron spin resonance (217), 13
Electroporation (219), 107
Electroporation, Piezo gas igniter (217), 249
Electrostatic charge (227), 47
Emulsification–diffusion (214), 25
Emulsion (212), 233; (214), 43; (215), 207; (227), 139
Emulsion solvent diffusion (218), 1; (220), 13
Enantiomers (224), 81; (229), 147
Energetics of formation (229), 213
Enhancer (212), 63; (220), 101; (228), 99, 161
Enoxacin (219), 61
Enteric polymer (229), 155
Entrapment efficiency (215), 185; (228), 43
Enzyme kinetics (212), 171
Epidermal permeability (217), 1
Eptifibatide (218), 43
Erosion (216), 165
Erythrocyte partitioning (215), 147
Erythrocytes (214), 99; (220), 43
Esophageal adhesion (222), 191
Esophageal transit (222), 295
ESR (220), 43
Esterification (212), 153
Estradiol (215), 91
Etching (226), 1
Ethambutol (228), 5
Ethanol (226), 69; (229), 213
Ethnic difference (222), 305
Ethylenediamintetraacetate (221), 115
Etilefrine (215), 83
EtOH (228), 181
Eucalyptol (224), 81; (229), 213
Eudragit® (213), 83, 93; (218), 1; (220), 13
Eudragit® L 100-55 (213), 7
Eudragit RL100 (218), 27
Eudragit RS100 (218), 27
Eudragit® S 100 (213), 7
Eutectic (219), 161

Eutectic composition (225), 49
Everted gut sac (213), 127
Excipient properties (227), 5
Experimental design (213), 175; (215), 123; (220), 129; (224), 115
Extrapolation (212), 275
Extrusion (217), 13, 237; (223), 55; (227), 71
Extrusion/spheronisation (213), 7; (222), 65

Factorial design (220), 129
Fatty acid (212), 63
Fatty acid carriers (228), 189
Fatty acid chain length (222), 217
Fatty acids (219), 161
FDC products (228), 5
Felodipine (218), 145
Fenoprofen (228), 129
Fentanyl (228), 69
Fermentation system (227), 157
FIA (216), 95
Fick's law (221), 49
Filler-binder (221), 77
Filling properties (227), 5
Film-coating (222), 295
Film system (224), 61
Filter (223), 55
Filterability (217), 201
FITC-dextran (226), 127
Fixed dose combination (FDC) (228), 53
Flavonols (213), 199
Floating dosage form (218), 103
Floating microparticles (220), 13
Flow cytometry (221), 35
Flow injection (221), 115
Fluid bed (220), 149
Fluidised bed (213), 63
Fluidity (217), 13
Fluidized bed coating (215), 3
Fluorescence (214), 55; (220), 43
Fluorescence resonance energy transfer (214), 77
6-Fluoroquinolones (220), 53
5-Fluorouracil (212), 153
Fluticasone propionate (221), 165
Focused beam reflectance (221), 165
Formamide (214), 43
Formulation (219), 51; (224), 105; (225), 1; (230), 35
Formulation excipients (225), 135
Formulation optimisation (227), 5
Formulation optimization (215), 123
Formulation stability (224), 169
Fourier transform infrared (225), 75
Fourier transform-infrared spectroscopy (219), 95
Fourier transform infrared spectroscopy (219), 11
Fractal geometry (224), 131
Fracture mechanics (227), 39
Fracture stress (227), 27
Franz diffusion cell (212), 73
Freeze-drying (219), 127
Freeze drying (218), 63
Freeze-drying (215), 137
FTIR spectroscopy (220), 33

Gacyclidine (229), 147
Gamma scintigraphy (212), 55; (217), 183; (230), 67
Gamma spectroscopy (222), 183
Gas antisolvent crystallisation (222), 129
Gas plasma (226), 1
Gastric emptying (227), 167
Gastric residence (212), 55
Gastro-intestinal secretions (222), 259
Gastrointestinal transit (228), 209
Gd–DOTA (212), 93
Gelatin (221), 219; (223), 69
Gelatin microparticles (219), 127
Gelatin microspheres (215), 175
Gelation temperature (226), 53
Gelcasting (213), 117
Gellan gels (220), 161
Gene transfer (218), 81; (225), 97
Genotype (229), 183
Gentamicin (217), 57
Glass transition (217), 45, 173; (218), 63; (219), 39; (225), 83
Glassy state (218), 145
Glutaraldehyde (213), 103; (220), 43
D,L-Glyceraldehyde (215), 175
Glycodeoxycholate (222), 109
Glycosaminoglycans (225), 113
Glycyrrhizic acid (217), 111
Granulation (212), 195; (219), 113
Granulation process (220), 149
Granule properties (220), 149
Granule size (229), 193

Gravimetric vapour sorption (227), 57
Griseofulvin (228), 19
Group contribution method (228), 199
Guinea pig (215), 197

Haemodialysis patients (229), 139
Hairless mouse skin (226), 47; (229), 131
Hairless rat skin (222), 57; (228), 69
Haloperidol (212), 247
Hanes-Woolf plot (212), 171
Hard capsules (227), 5
Hardness (230), 35
Heat (213), 45
Hemagglutination (214), 99
Hemoglobin (215), 185
Heparin sodium salt (228), 147; (229), 117
HFA-134a (221), 165
High concentration (214), 21
High pressure homogenisation (214), 21; (223), 89
High-pressure homogenization (213), 175
HIV (214), 83
HLB (220), 63
Homogenised mucus (217), 87
Hot stage microscopy (219), 39
HPLC (212), 109; (213), 199; (217), 111, 153; (223), 49
HPMC see hydroxypropylmethylcellulose
HPMCAS HF (216), 165
HPTLC (228), 53
Human (221), 87
Human epidermis (212), 131
Human growth hormone (229), 107
Human plasma (224), 201
Human skin (228), 69
Human-skin culture (215), 51
Humidity (223), 1
Hyaluronan (225), 113
Hydration (215), 251
Hydrochlorothiazide (222), 1
Hydrocolloid tablets (216), 165; (217), 139
Hydrocortisone (212), 153; (215), 51
Hydrocortisone acetate (212), 213; (221), 95
Hydrodynamic radius (229), 213
Hydrodynamic stress (217), 139
Hydrofluoroalkane (222), 101
Hydrogel (215), 57; (218), 57; (224), 151
Hydrogels (213), 143; (224), 89; (228), 33
Hydrogen bonding (212), 213
Hydrolysis (217), 161
Hydrolyzed gelatin (221), 219
Hydrophilic drug (220), 63
Hydrophilic solutes (225), 75
Hydrotrope (213), 25
Hydrotropy (213), 25
Hydrous form (217), 225
Hydroxyanthracenones (229), 23
Hydroxyapatite (213), 117
7α-hydroxylase (229), 75
3-hydroxy-3-methylglutaryl coenzyme A reductase (229), 75
2-Hydroxypropyl-β-cyclodextrin (229), 163
Hydroxypropyl-β-cyclodextrin (213), 75; (215), 137; (218), 113
2-Hydroxypropyl-β-cyclodextrin (212), 131
Hydroxypropyl - β - cyclodextrin : Px complexes (229), 37
Hydroxypropylmethylcellulose (212), 131, 187, 195; (213), 75; (215), 3; (216), 115; (219), 39; (222), 7; (226), 53
Hydroxypropylmethyl cellulose (222), 7
Hydroxypropylmethylcellulose acetate succinate (216), 137; (217), 33; (218), 103
Hygroscopicity (216), 127
Hypercholesterolemia (229), 75
Hyperforins and hypericins (213), 199
Hyperphosphatemia (223), 29
Hypoglycemic effect (212), 289; (218), 75

Ibuprofen (212), 131; (218), 1; (220), 23; (224), 39; (225), 113; (228), 119; (229), 155
Idarubicin (220), 43
I.m administration (230), 67
Immune response (217), 249
Immunocompromised (214), 103
Immuno-liposomes (215), 45
Immuno-magnetic (215), 45
Immunostimulation (222), 237
Immunotoxin (221), 175
Implant (213), 103
Implantable drug delivery systems (213), 117
Impurity incorporation (215), 29
Inclination of the rotation axis (224), 141

Inclusion complex (218), 113
Inclusion complexation (229), 163
Inclusion complexes (212), 177
Indomethacin (222), 57; (226), 81, 147
Indomethacin pellets (230), 25
Induction period (215), 29
Infection (214), 103
Inhalation therapy (228), 219
Inhaled therapy (222), 101
Inhibitors (225), 31
In situ gelation (220), 161; (229), 29
Instruction (228), 219
Instrumented machines (227), 5
Insulin (212), 289; (216), 105; (217), 25; (218), 75; (220), 101; (225), 31
Insulin stability (217), 111
Integrilin (218), 43
Interaction (226), 61, 81
Interactions (229), 23
Intercalation (220), 23
Interfacial behaviour (214), 49
Internal energy change (213), 45
Intestinal absorption (221), 87; (228), 181
Intestinal transport (219), 1
Intestinal water uptake (229), 95
Intracellular bioreductive activation (219), 1
Intragranular porosity (222), 65
Intramuscular administration (215), 13
Intramuscular injection (212), 11
Intranasal (217), 121
Intranasal administration (213), 187
Intranasal drug delivery system (226), 127
Inulin (213), 143; (215), 163
Inverse phase gas chromatography (217), 45; (221), 211
In vitro (214), 83; (218), 81; (228), 79
'In vitro' drug diffusion (217), 57
In vitro drug release (222), 45
In vitro–in vivo correlation (230), 1
In vitro permeation (221), 95
In-vitro pig esophageal model (222), 191
In vitro release (217), 57; (220), 23
In-vitro skin delivery (219), 73
In vitro study (228), 147
In vivo transfection (221), 23
Ion-exchange (220), 23
Ion-exchange resin (212), 55; (216), 67
Ionic species (217), 71
Ionization (212), 29
Iontophoresis (212), 101; (214), 31; (215), 57, 241; (218), 57, 93; (229), 37
γ-irradiation (222), 205
Irradiation (221), 69
Irritation (222), 225
Isoniazid (228), 5, 53
Isoquinoline (217), 101
Isothermal microcalorimetry (227), 57
Isoxsuprine (215), 83
Itraconazole (213), 163; (229), 193

Jet nebuliser (227), 121
Jugular vein (216), 61

*Karwinskia* (229), 23
Keratinase (224), 115
Keratinocytes (221), 23
6-ketocholestanol (217), 79
Ketoconazole (226), 61
Ketoprofen (219), 81; (220), 13; (222), 225; (228), 161
Ketotifen fumarate (223), 15
Kinetics (215), 251
$K_{IPM:AQ}$ (217), 127

Lacidipine (226), 147
Lactate dehydrogenase (220), 101
Lactosaminated *N*-succinyl-chitosan (226), 93
Lactose (216), 43, 127
Lactose monohydrate (227), 39
Lag time (217), 33
Langmuir equation (213), 31
Lavage fluid (217), 25
LDL (228), 109
Lecithin vesicles (216), 17
Lectin (221), 35
Leuprolide acetate (215), 241
Lidocaine (222), 35; (223), 49
β-ligands (228), 171
Limonene (224), 81
Linear mixed models (226), 107
Lipid (212), 187

Lipid extraction (215), 241; (225), 75
Lipidic peptide dendrimer (214), 71
Lipolytic degradation products (222), 217
Lipophilic compounds (222), 77
Lipophilicity (216), 83
Lipopolymer (214), 63, 67, 93
Liposome (212), 109; (213), 175; (217), 161; (221), 197; (223), 55; (228), 147; (229), 117
Liposome–dendrimer interactions (214), 71
Liposomes (213), 153; (214), 17, 67, 71, 93; (215), 45, 197; (216), 105; (219), 61, 139; (223), 15; (224), 69; (228), 43
Liquid consumption (227), 97
Liquid crystals (212), 73; (213), 1
Liquisolid tablets (222), 1
Liver uptake (229), 173
Local anesthetic (218), 57
log *P* (220), 53
Longitudinal data (226), 107
Loose density (216), 159
Lorazepam (216), 1; (228), 79
Loss modulus (228), 139
Low crystallinity cellulose (222), 121
Lubrication (215), 123
Luteinizing hormone-releasing hormone (216), 77
Lyophilization (223), 15; (226), 39
Lyophilized dispersions (229), 67
L-lysine monohydrochloride dihydrate (215), 221
Lysophosphatidylcholine (222), 109
Lysosomotropic agents (218), 81

Machine simulators (227), 5
Macromolecular prodrug (223), 35; (228), 129
Magnesium stearate (216), 137; (218), 153
Magnetic (215), 45
Magnetic resonance imaging (222), 243
Maize starch (220), 85
Malic acid polymer (226), 31
Malignant melanoma (212), 257
Matrix pellets (219), 81
Matrix swelling (215), 175
Matrix tablets (216), 115
MDCK cells (215), 263
Mechanical properties (227), 27
Mechanisms of action (227), 149
Melatonin (212), 63
Melphalan (219), 1
Melt dispersion (218), 133
Melt extrusion (226), 147
Melt granulation method (216), 159
Melting point (228), 89
Melting point depression (222), 35
Membrane transport (213), 1; (222), 281; (229), 87
l-Menthol (226), 69
Menthone (219), 177
Metabolism (227), 157
Metastable form (217), 225
Methacrylic acid (218), 13
Methotrexate (212), 101; (215), 57
[methyl-$^{14}$C, 8-$^{3}$H]SAM (230), 47
Methyl hydroxyethyl cellulose (MHEC) (217), 139
Methylmethacrylate (219), 89
Methyl methacrylate (218), 13
Mg–Al hydrotalcite (220), 23
MHEC (216), 165
Mice BALB/C (221), 175
Micelle (220), 141; (221), 197
Micelle formation (214), 49
Micelles (216), 23
Micellization (229), 57
Miconazole (220), 129
Microcalorimetry (216), 43
Microcapsule (216), 67
Microcrystalline cellulose (213), 13; (216), 147; (217), 237; (222), 65; (228), 139; (230), 25
Microcrystalline cellulose pellets (219), 113
Microdialysis (216), 61; (229), 147
Microemulsion (215), 57; (216), 17; (222), 45; (228), 161; (229), 213
Microemulsions (222), 271; (226), 47
Microencapsulation (212), 187; (215), 185; (218), 1, 133
Microenvironment PH (223), 81
Microfluidizer (213), 175
Microparticles (212), 11; (215), 153; (218), 13
Microparticulates (225), 31
Microscopy (212), 109
Microsphere (212), 161; (218), 125; (220), 91
Microwave-enhanced (220), 33
Midazolam (213), 187
Minimal inhibitory concentration (220), 53
Minodronic acid (222), 91
Mitomycin C (226), 93
Mixed films (226), 139
Mixed hydrophilic matrices (222), 7

Mixing (222), 243
Mixing efficiency (224), 141
Mixing performance (217), 201
M5076 liver metastasis (226), 93
Mode III loading (227), 39
Model drugs (217), 237
Modeling (229), 95
Model solvent system (224), 51
Mode of administration dependency (220), 1
Mode of deformation (222), 65
Modification of Clausius–Mossotti/Debye equation (225), 123
Modulated differential scanning calorimetry (230), 35
Modulated temperature DSC (213), 163
Modulation (228), 171
Moisture (217), 173; (223), 1
Moisture sensitivity (221), 49
Moisture sorption–desorption (215), 137
Moisture sorption desorption isotherms (212), 177
Molecular mobility (213), 163
Molecular weight (218), 63
Monohydroxylation (212), 153
Monomethoxypoly(ethylene oxide)–poly(lactic acid) (212), 1
Morphine (212), 275; (229), 131
Mouthwash (220), 111
MRI (212), 93
Mucoadhesion (214), 3, 83; (217), 87; (222), 121
Mucoadhesive (224), 61
Mucoadhesive microspheres (224), 123
Mucoadhesive polymer (215), 101; (220), 169
Multidrug resistance (222), 169
Multiparticulates (216), 9
Multiple emulsion (214), 31
Multiple-unit tablet (229), 155
Multivariate calibration (229), 205
Muscle damage (212), 11
Mydriatic effect (213), 75
Myotoxicity (212), 11

Nail keratins (224), 115
Nalbuphine propionate (220), 91
Naloxone (219), 95
Nanocapsules (214), 13
Nanocrystals (219), 81
Nanoemulsions (220), 63
Nanoparticle (214), 25; (226), 23
Nanoparticles (214), 13, 55, 87; (218), 75, 113; (224), 159; (228), 19; (230), 11
Nanospheres (214), 13, 21, 37
Nanosuspension (214), 3, 21, 83
Nasal absorption (226), 127
Nasal administration (212), 267
Nasal delivery (221), 227; (222), 109; (224), 105
Nasal drug delivery (217), 183
*NAT*2* (229), 183
Near infrared hydrophilic/hydrophobic model (214), 37
Near infrared spectroscopy (227), 57
Nebulisation (215), 113
Nedocromil magnesium pentahydrate (215), 251
Negatively charged membranes (214), 77
Neutropenic cancer patients (213), 153
*N*-(2-hydroxyethyl)pyrrolidine (222), 281
Nicardipine hydrochloride (218), 103
Nicotinamide (219), 39; (226), 53
Nicotinic acid ester (216), 83
Niosomes (215), 91; (219), 61; (228), 43
Nitrendipine (215), 147
Nitrosoureas (212), 257
Nitroxyl free radical (212), 257; (222), 237
*N*-ole-1-oyltaurate (230), 47
Non-aqueous emulsions (214), 43
Non-competitive inhibition (212), 171
Non-ionic surfactants (212), 73; (215), 91
Nonivamide (222), 225; (224), 89
Nonlinear clearance (229), 173
Nonlinear pharmacokinetics (220), 1; (229), 173
Non-specific binding (222), 77
Non-viral gene delivery (229), 1
Non-viral vectors (221), 23
Norfloxacin (216), 127
Novel diffusion cell (229), 87
NSC-639829 (225), 41
*N*-Succinyl-chitosan (226), 93
Nucleation time (212), 213

*Ocimum* oil (224), 177
Ocular (224), 159
Ocular bioavailability (215), 101; (220), 169
Ocular drug delivery (215), 101; (220), 169; (229), 29

Ocular insert (215), 101; (220), 169
*O*-Ethylmenthol derivatives (212), 223
Ofloxacin (215), 101; (220), 169
Oily gel (222), 57
Oily solutions (216), 83
Oleyl alcohol (229), 131
Olfactory pathway (212), 267
Oligonucleotide delivery (214), 25
Oligonucleotides (214), 13
Oligopeptide transporter (220), 119
Oligosaccharide (224), 19
Ophthalmic vehicles (213), 75
Optimization (213), 93; (220), 149
Oral absorption (222), 77
Oral administration (216), 105; (218), 113
Oral delivery (216), 77
Oral drug delivery (220), 161
Oral lichen planus (220), 111
Organoemulsion (214), 43
Oscillatory testing (214), 9
Osmolality (213), 187
Oxedrine (215), 83
Oxidation (212), 275
Oxidized cellulose (223), 35
Oxidized cellulose conjugate (223), 35
Oxycodone (223), 49

Package (221), 49
Packaging (223), 1
Pain reduction (220), 141
Palygorskite (217), 201
Pan coater (224), 141
Pancreatic endopeptidases degradation (216), 77
Pan speed (224), 141
Parabens (213), 31
Paracetamol (215), 29
Paracetamol tablets (230), 25
Parenteral depots (216), 83; (230), 67
Parenteral emulsions (216), 1
Parenteral formulation (222), 91
Partial solubility parameters (228), 199
Particle fragmentation (215), 221
Particle size (215), 221; (217), 161; (223), 55; (227), 47
Partition coefficient (222), 217; (225), 113
Partition coefficients (220), 53
Pattern-fitting (212), 203
PCM (229), 45
Pectin (226), 139
Pediatric (212), 93
PEG 20000 (229), 193
PEG (228), 181
PEG 6000 (225), 49
PEG 4000 (222), 129
PEG-liposomes (214), 93
PEG liposomes (214), 63, 67
PEG-25 PABA (222), 153
Peldesine (219), 73
Pellet compactability (227), 81
Pellet deformability (227), 81
Pelletisation (227), 81
Pellets (213), 7, 83; (216), 9; (227), 71
Penetration (222), 153
Penetration enhancers (212), 247; (219), 73, 177; (228), 79, 89
Penicillin G sulfoxide (220), 33
PepT1 (220), 119
Peptide delivery (214), 31
Peptide–membrane association (214), 77
Percent porosity (213), 45
Percent solids (213), 45
Percutaneous absorption (215), 51; (219), 177; (224), 169; (225), 75
Percutaneous absorption enhancer (212), 223
Percutaneous penetration (217), 1; (228), 147
Percutaneous permeation (213), 193
Peritoneal macrophages (221), 57
Permeability (215), 241; (222), 77; (225), 15; (226), 139; (228), 181
Permeability coefficients (213), 127
Permeation (212), 131; (215), 91; (216), 51; (220), 111; (222), 199
Permeation enhancement (226), 69, 185
Permeation enhancer (222), 199
Permeation study (217), 153
Peroxisomicine (229), 23
P-glycoprotein (228), 171
pH (213), 187; (226), 69; (227), 167; (228), 181
Pharmaceuticals (216), 95
Pharmaceutical statistics (226), 107
Pharmacokinetic (222), 1; (230), 47
Pharmacokinetic-hematocrit dependence (215), 147

Pharmacokinetics (215), 147; (216), 17; (217), 101; (220), 1; (221), 143; (222), 305; (229), 45, 183
Pharmacopoeia limits (221), 159
Phase separation (215), 3; (219), 127
Phase solubility analysis (212), 177
Phase transition (221), 123
Phase transition temperature (221), 197
pH control (216), 165
pH-dependent solubility (216), 165
Phenotype (229), 183
Phenylalanine ammonia lyase (215), 185
Phenylpropanolamine (223), 35
Phenytoin (225), 63
Phenytoin and *p*HPPH (229), 45
Phloretin (217), 79
Pholedrine (215), 83
Phonophoresis (229), 131
Phosphate (223), 29
Phosphatidylcholine (217), 161; (222), 57; (223), 55
Phosphatidylethanol (216), 105
Phospholipase $A_2$ (214), 67
Phospholipid (213), 175; (221), 197
Photodesorption (226), 1
Photolabile drugs (225), 1
Photo-stability (229), 163
Phototoxicity (218), 27
pH-sensitive (212), 19; (228), 33; (230), 11
Phospholipase $A_2$ (214), 93
Phthalic acid (224), 151
Physical–chemical characterisation (217), 57
Physico-chemical characterisation (222), 129
Picking (215), 123
Pig (230), 67
Pig vesical mucosa (224), 123
Pilocarpine hydrochloride (229), 29
Piroxicam (222), 45, 199
Plasmid DNA (218), 81
Plastic ampoules (212), 275
Plasticizer (217), 33
PLGA-microparticles (226), 181
Pluronic F-127 gels (212), 289
PMMA bone cements (217), 57
Poloxamer (221), 197; (222), 199
Poloxamer gel (226), 195
Poloxamines (229), 57
Polyacrylate gels (219), 139
Poly(acrylic acid) (217), 87
Poly amidoamine (PAMAM) (215), 263
Poly(amino acids) (230), 11
Polyanhydride (219), 151
Poly-L-arginine (226), 127
Polybutylcyanoacrylate (218), 75
Poly(ε-caprolactone-co-DL lactide) (212), 121
Polycarbophil (224), 123
Polycarbophil–cysteamine conjugate (226), 185
Poly(2-dimethyl amino ethyl)methacrylate (214), 99
Polydispersity (214), 55
Poly (d,l-lactide-co-glycolide) (220), 91
Poly(ethylene glycol) (219), 127; (226), 23
Polyethylene glycol 300 (217), 121
Polyethylene glycol (216), 9
Polyethylene glycol 6000 and polyvinyl-pyrrolidone K-30 (225), 63
Polyethylene glycol-poly(L-lactide) diblock co-polymer (215), 67
Poly(ethylene oxide) (215), 101; (220), 169; (224), 151
Polyglycolyzed glycerides (212), 233
Polyisobutylcyanoacrylate (214), 13
Poly(D,L-lactic acid) (212), 161; (214), 25
Poly(D,L-lactic-co-glycolic acid) (229), 107
Poly(lactide-co-glycolide) (214), 31; (221), 143
poly(Lactide-co-glycolide)-monomethoxy (polyethyleneglycol) (221), 143
Poly(L-lactide)/polyethylene glycol-poly(L-lactide) blending (215), 67
poly(MePEGcyanoacrylate-co-hexadecyl cyanoacrylate) (214), 37
Polymer (222), 139
Polymer conjugate (223), 35
Polymer-drug conjugate (228), 129
Polymeric conjugate (226), 23
Polymeric vesicles (229), 1
Polymer mixtures (216), 115
Polymer particle erosion (217), 139
Polymers (212), 213; (224), 169; (229), 1
Polymethacrylates (213), 83, 93
Poly(methyl glyoxylate) (229), 67
Poly(methylmethacrylate) (219), 89
Polymorphic form (217), 225
Polymorphism (213), 209
Polymorphs (225), 49

Poly[α,β-(*N*-2-aminoethyl-DL-aspartamide]-
poly[α,β-(*N*-2-hydroxyethyl-DL-aspartamide)]-copolymer (228), 129
Poly[α,β-(*N*-2-hydroxyethyl-DL-aspartamide)] (228), 129
Poly[α,β-(*N*-3-hydroxypropyl-DL-aspartamide)] (228), 129
Poly-*N*-isopropylacrylamide (222), 259
Poly(*N*-vinyl 2 pyrrolidone/itaconic acid) (228), 33
Polyphosphazene (219), 151
Polysaccharides (224), 19
Polysialic acids (217), 215
Polysoap (224), 185
Poly(vinylpyrrolidone) (225), 83
Polyvinylpyrrolidone (213), 75; (218), 63
Porcine skin (215), 241; (217), 79; (226), 181
Porosity (212), 177; (216), 137; (219), 113; (227), 81
Porous ceramic (213), 117
Porous structure (223), 69
Post antibiotic effect (227), 149
Potts-Guy equation (217), 127
Powder (224), 105; (227), 5
Powder plug formation (227), 5
Precipitate (222), 91
Prediction (220), 119; (221), 87
Preferred orientation (212), 203
Preformulation (217), 101
Press-coated tablets (216), 137; (217), 33
Pressurized metered-dose inhaler (222), 101
Principal component analysis (212), 41
Probucol (222), 139
Prodrug (229), 173
Prodrugs (216), 83
Progesterone (229), 67
Programmable drug delivery (219), 151
Prolonged release (216), 67
Proniosomes (215), 91
Propofol (215), 207
Propranolol (219), 161
Propylparaben (229), 205
Protein activity (212), 1
Protein adsorption (214), 87
Protein aerosol (227), 121
Protein C (212), 1
Protein delivery (217), 215
Protein release (212), 1
Psoriasis (212), 101; (215), 57
Pulmonary (223), 15
Pulmonary absorption (220), 101
Pulmonary administration (218), 75
Pulmonary delivery (217), 25
Pulse depolarization (218), 93
Purine nucleoside inhibitor (219), 73
PVC (229), 139
PVP (218), 81
Pyrazinamide (228), 5
Pyrene (224), 185
Pyroglutamate aminopeptidase (212), 171

QSBR (226), 207
Quality control (221), 175
Quantitation (214), 55
Quantitative analysis (212), 203
Quartz crystal microbalance (222), 121
Quaternary ammonium palmitoyl glycol chitosan (224), 185
Quinolones (227), 149

Rabbits (213), 75
Radiotelemetry (227), 167
Ram extruder (216), 147
Ranitidine (227), 157
Rapamycin (213), 25
Rat (212), 267; (215), 197; (218), 75; (221), 227; (224), 61; (229) 45; (230), 47
Rate of drug release (212), 73
Rat intestinal BBMV (220), 119
Rat skin (212), 73, 247; (222), 199
Receptor–ligand interaction (214), 63
Recirculating perfusion technique (229), 95
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) (226), 127
Rectal gel (223), 49
Redispersibility (212), 187, 195
Regression model (220), 149
Regular solutions (225), 123
Rehydrated freeze-dried liposomes (215), 113
Relative bioavailability (216), 17
Relative release rate (216), 83
Relaxation (220), 85
Release from adhered microspheres (224), 123
Release in vitro (230), 1

Release mechanism (216), 115; (228), 189
Release model (219), 89
Release study (217), 153
Remanence (222), 153
Reservoir-type (219), 51
Resistivity (228), 219
Resorcinol (224), 151
Retention (224), 61
Rhenium VII oxide (222), 183
Rheological properties (216), 147
Rheological synergy (217), 87
Rheology (214), 9; (215), 13; (222), 7
Rheology of creams (221), 187
Rhodamine (226), 181
Ricin (221), 175
Rifampicin (228), 5, 53; (230), 1
Risedronate (222), 191, 295
Roll compactor (220), 129
Roughness (218), 145

Saccharin (224), 131
Salbutamol (222), 101
Salicylazosulfapyridine (229), 183
Salicylic acid (215), 51; (216), 51, 95; (224), 151
Salmeterol xinafoate (216), 33; (221), 165
Salmon calcitonin (218), 93
Salt form (223), 81
Salting-out (215), 3
Salts (222), 259; (226), 163
$S_{AQ}$ (217), 127
Saquinavir (218), 113
S.c. administration (230), 67
Scintigraphy (222), 295
Screening (221), 87
Sebum (220), 63
Secondary structure (230), 11
SEDDS (212), 233
Segregation (222), 243
Segregation index (222), 243
Self-assembly (230), 11
Self-emulsifying drug delivery systems (212), 233
Self emulsifying system (227), 139
Sepiolite (217), 201
Sequential lipid–lysine polymers (214), 49
Shear viscosity (229), 213
Sheep hoof keratins (224), 115
Sheep model (217), 183
Shelf life (212), 275
Shellac (223), 89
Silica xerogel (212), 121; (221), 107
Silicified microcrystalline cellulose (216), 147
Silicone membrane (216), 51; (221), 95
Similarity factor (220), 77, 129
Similarity factor $f_2$ (212), 41
Simulated gastric media (212), 81
Simulated skin (213), 193
Single pass technique (229), 95
$S_{IPM}$ (217), 127
Site-specific delivery (213), 83
Site-specific drug delivery (217), 193
Size (221), 57; (228), 109
Skin (224), 89
Skin absorption (228), 99
Skin concentration (219), 107
Skin impedance (217), 249
Skin penetration (217), 1; (224), 81, 169; (229), 117
Skin permeation (219), 61; (228), 43
Skin permeation (212), 153; (219), 107; (222), 57; (226), 69
Skin pretreatment (229), 37
Skin retention (229), 37
Skin reversibility (219), 177
Skin slicing (226), 181
Skin transport (220), 63
Small-angle neutron scattering (213), 1
Small intestine (224), 61
Smectite (217), 201
Sodium ascorbyl phosphate (222), 271
Sodium chloride (226), 195
Sodium citrate (212), 19; (215), 3
Sodium dodecylsulphate (216), 23
Sodium lauryl sulfate (218), 125
Sodium lauryl sulphate (213), 13
Sodium taurodihydroxyfusidate (222), 109
Soft gelatin capsule (230), 35
Solid dispersion (218), 27, 125; (222), 139; (225), 49
Solid dispersions (222), 129; (225), 63
Solid dosage forms (212), 203
Solid-in-oil-in-water emulsion (219), 127
Solid lipid nanoparticles (214), 9; (221), 57
Solid phase spectrophotometry (216), 95
Solid solution (229), 193

Solid-state characterisation (221), 123
Solid-state NMR (226), 81
Solid-state properties (217), 225
Solubilisation (224), 185
Solubility (212), 29; (213), 25, 127; (216), 33; (220), 141; (221), 219; (222), 217, 281; (228), 199; (229), 163
Solubility parameter (225), 83, 123; (226), 147
Solubilization (213), 25, 75; (225), 41; (229), 67
Soluble proteins (224), 115
Solutions (228), 5
Solvent evaporation (212), 161; (218), 133
Solvent system (219), 95
Solvophilicity (214), 43
Somatostatin (218), 133
Sonophoresis (228), 69
Sorption (223), 1
Spacer (228), 129
Spacer devices (222), 101
Specific heat (217), 173
Spectrophotometry (229), 205
Spectroscopy (225), 83
Spheronisation aid (230), 25
Spheronization (227), 71
Spinal cord (229), 147
Spin labeled (212), 257
Spin labeled nitrosoureas (222), 237
Spore (226), 1
Spray drying (216), 43
Spray-drying (215), 137
Spray drying (212), 187, 195; (213), 209
Spray rate (224), 141
Spreading coefficients (227), 97, 113
Spreading mechanism (215), 13
Stability (212), 93; (215), 207; (216), 9, 23; (218), 43; (219), 139; (221), 49; (222), 91, 271; (223), 1, 81; (225), 135; (227), 133; (228), 1, 43
Stability testing (225), 1
Stabilization (215), 163
Starch (221), 69
Starch characterisation (221), 69
Starch microspheres (222), 109
Static rheological tests (221), 187
Statin drugs (229), 75
Statistical optimization (213), 175
Stearic acid (228), 189
Sterically stabilized liposomes (214), 103
Steric stabilization (214), 63
Sterilisation (217), 161
Sterilization (226), 1
Steroids (228), 171
Sterol 27-hydroxylase (229), 75
Stimulation (220), 85
St. John's wort (*Hypericum perforatum* L.) (213), 199
Stomach (228), 209
Storage (224), 39
Storage conditions (221), 187
Storage modulus (228), 139
Storage time (221), 187
Stratum corneum (217), 1; (225), 75
Stratum corneum uptake (228), 89
Strength testing (227), 27
Striatum (216), 61
Stripping (222), 153
Structure–activity relationship (212), 223
Subsite specificity (216), 77
Substituted amylose (222), 183
Succinoylation (230), 57
Sucralfate (212), 55
Sucrose (218), 63, 81
Sugar coated tablets (224), 39
Sugar glasses (215), 163
Sulfobutyl ether β-cyclodextrin (212), 177; (229), 163
Supercritical $CO_2$ (228), 19
Supercritical fluids (222), 129
Supersaturation (212), 131; (221), 95; (224), 169
Surface area (218), 153
Surface area analysis (212), 177
Surface energetics (227), 113
Surface energy (217), 45
Surface erosion (213), 7
Surface free energy (221), 211
Surface modification (221), 57
Surface tension (212), 81
Surface topography (218), 145
Surfactant (212), 81; (214), 21; (219), 81; (221), 57, 187, 197; (222), 199, 259; (228), 99
Surfactant-free (223), 89
Survival curve (226), 1
Sustained release (215), 13; (219), 81; (220), 13, 161; (226), 31; (229), 29, 107
Sweetener excipient (224), 131

Syringes (212), 93

Tablet (221), 49, 77; (222), 295; (226), 61
Tablet coating (227), 113
Tablet formulation (212), 195
Tableting (215), 137, 221
Tableting properties (217), 225
Tamoxifen (214), 37; (219), 177
Tape-stripped skin (228), 147
Tape stripping (219), 11
Teflon (228), 209
Temperature (224), 141
Temperature modulated DSC (217), 173
Tenoxicam (221), 227
Tensile strength (215), 221
Terbinafine (215), 51
Terbinafine hydrochloride (228), 33
Terpenes (224), 81; (228), 89; (229), 37
α-Terpineol (229), 131
Terpinolene (224), 81
*tert*-Butylamine (226), 163
Tertiary butyl alcohol (226), 39
Testosterone (219), 51
Test specimens (227), 27
Tetracaine (229), 87
Tetramethylpyrazine (216), 61
Theophylline (217), 225
Theoretical QSAR (217), 1
Therapeutic proteins (215), 163
Thermal analysis (219), 161; (226), 147; (230), 35
Thermal and photostability (213), 199
Thermally pregelatinized waxy maize starch (222), 7
Thermogravimetry (213), 31
Thermomechanical analyzer (228), 139
Thermogravimetric analysis (216), 43
Thermoresponsive polymers (222), 259
Thermosensitive (226), 195
Thickness shear mode sensor (222), 121
Thiomers (226), 185
Three-point beam-bending (228), 139
Thymol (222), 35
Tissue engineering (221), 1
α-Tocopherol (222), 217
Tolbutamide (215), 137
Tomato lectin (215), 153
Topical (222), 271; (224), 159; (225), 15
Topical administration (219), 11
Topical application (214), 9; (224), 89
Topical bioavailability (219), 11
Topical delivery (228), 43
Topical drug delivery (224), 169; (226), 181
Topical vehicles (219), 11
Toremifene citrate (212), 121
Torque (227), 97
TOTM (229), 139
Transcription inhibitory activity (214), 37
Transdermal (212), 247; (219), 51
Transdermal administration (218), 93
Transdermal delivery (212), 63; (228), 69, 79, 161
Transdermal drug delivery (229), 131
Transdermal permeation (219), 95, 161; (226), 47
Transdermal preparation (217), 153
Transdermal system (224), 81
Transfection (214), 99
Transfollicular (220), 63
Transmission electron microscopy (213), 1
Transport (215), 263; (222), 169
Transwell® (224), 201
Tretinoin (221), 123
Triamcinolone acetonide (220), 111
Triangular phase diagram (218), 1
Triazenes (212), 257
Triboelectrification (227), 47
Triethyl citrate (217), 33
Trifluorothymidine determination (222), 205
Triglycerides (218), 133
Tris(hydroxymethyl)aminomethane (226), 163
Tristimulus colorimeter (213), 63
Tropicamide (213), 75
Trypanosomiasis (214), 87
Turbula® (222), 243
Tween 85 (220), 141
Tween 20 (220), 141
Twin-screw extruder (218), 103
Two-dimensional electrophoresis (214), 87
Two-phase melt systems (222), 35
Type II cells (217), 25
Type of diluent (227), 97
Tyramine (215), 83

Ultra-fine grades (213), 13; (230), 25
Ultrasonic homogenisation (213), 13
Ultrasonic nebuliser (227), 121

Ultrasound (216), 1; (228), 19; (229), 131
Ultraviolet absorption method (228), 1
Unit dose dispensing packs (224), 39
Unloading (213), 45
Unloading heat (213), 45
Unloading work (213), 45
Unsaturated fatty acids (212), 289
Uptake (219), 1
Urinary excretion (228), 53
UV irradiation (226), 1
UV–Vis spectroscopy (229), 23

Vacuum mixing (219), 89
Vaginal application (219), 139
Vapor pressure (213), 31
Vehicle (212), 63
Verapamil HCl (228), 119
Vesicle (217), 13, 161; (223), 55
Virus microencapsulation (221), 153
Virus neutralisation (221), 153
Viscoelasticity (214), 9
Viscometry (224), 185
Viscosity (219), 139; (226), 53
Viscosity of granulating liquid (227), 97
Volume of distribution (220), 1
Washing (220), 33
Water content (218), 153
Water–Dioxane (216), 33
Water-in-oil nanoemulsions (221), 23
Water penetration (222), 7
Water retention (217), 237
Wet granulation method (216), 159
Wetting (212), 81
Wheat germ agglutinin (221), 35
Wilhelmy plate method (221), 211
W/o emulsions (215), 13
Work (213), 45
Wurster process (216), 67

X-ray (221), 69
X-ray diffraction (212), 177
X-ray powder diffraction (212), 203
Xyloglucan gels (220), 161; (229), 29

Yield strength (215), 221
Young's modulus (228), 139

Zero-order release (217), 139
Zeta potential (223), 89; (228), 109; (229), 117
Zeta potentials (214), 99
Zinc–insulin suspensions (217), 71